US20210230533A1 - Apparatus and method for performing microorganism detection - Google Patents
Apparatus and method for performing microorganism detection Download PDFInfo
- Publication number
- US20210230533A1 US20210230533A1 US17/140,696 US202117140696A US2021230533A1 US 20210230533 A1 US20210230533 A1 US 20210230533A1 US 202117140696 A US202117140696 A US 202117140696A US 2021230533 A1 US2021230533 A1 US 2021230533A1
- Authority
- US
- United States
- Prior art keywords
- reservoir
- virus
- unit
- valve opening
- collector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000001514 detection method Methods 0.000 title claims abstract description 122
- 238000000034 method Methods 0.000 title claims abstract description 73
- 244000005700 microbiome Species 0.000 title claims abstract description 42
- 241000700605 Viruses Species 0.000 claims abstract description 113
- 241000907316 Zika virus Species 0.000 claims abstract description 59
- 239000000872 buffer Substances 0.000 claims description 93
- 230000003321 amplification Effects 0.000 claims description 61
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 61
- 239000007788 liquid Substances 0.000 claims description 60
- 230000007246 mechanism Effects 0.000 claims description 28
- 108020004707 nucleic acids Proteins 0.000 claims description 25
- 102000039446 nucleic acids Human genes 0.000 claims description 25
- 150000007523 nucleic acids Chemical class 0.000 claims description 23
- 230000008878 coupling Effects 0.000 claims description 10
- 238000010168 coupling process Methods 0.000 claims description 10
- 238000005859 coupling reaction Methods 0.000 claims description 10
- 241000894006 Bacteria Species 0.000 claims description 8
- 241000588724 Escherichia coli Species 0.000 claims description 8
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 6
- 241000712461 unidentified influenza virus Species 0.000 claims description 6
- 238000005406 washing Methods 0.000 claims description 5
- 241000725619 Dengue virus Species 0.000 claims description 4
- 241001502567 Chikungunya virus Species 0.000 claims description 3
- 241001115402 Ebolavirus Species 0.000 claims description 3
- 241000711549 Hepacivirus C Species 0.000 claims description 3
- 241000700721 Hepatitis B virus Species 0.000 claims description 3
- 241000709721 Hepatovirus A Species 0.000 claims description 3
- 241000608292 Mayaro virus Species 0.000 claims description 3
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 3
- 241000191967 Staphylococcus aureus Species 0.000 claims description 3
- 241000193998 Streptococcus pneumoniae Species 0.000 claims description 3
- 229940031000 streptococcus pneumoniae Drugs 0.000 claims description 3
- 238000012360 testing method Methods 0.000 abstract description 36
- 230000035945 sensitivity Effects 0.000 abstract description 24
- 241000711573 Coronaviridae Species 0.000 abstract description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 71
- 239000000523 sample Substances 0.000 description 57
- 239000000443 aerosol Substances 0.000 description 54
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 37
- 208000037801 influenza A (H1N1) Diseases 0.000 description 28
- 201000010740 swine influenza Diseases 0.000 description 28
- 108091093088 Amplicon Proteins 0.000 description 15
- 208000020329 Zika virus infectious disease Diseases 0.000 description 15
- 239000000463 material Substances 0.000 description 15
- 238000002156 mixing Methods 0.000 description 15
- 210000002700 urine Anatomy 0.000 description 15
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 13
- 241001678559 COVID-19 virus Species 0.000 description 12
- 108020004414 DNA Proteins 0.000 description 12
- 238000002123 RNA extraction Methods 0.000 description 12
- 238000011534 incubation Methods 0.000 description 12
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 11
- 108020000999 Viral RNA Proteins 0.000 description 11
- 238000003556 assay Methods 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 238000004587 chromatography analysis Methods 0.000 description 11
- 229920000515 polycarbonate Polymers 0.000 description 11
- 239000004417 polycarbonate Substances 0.000 description 11
- 239000000203 mixture Substances 0.000 description 10
- 238000005070 sampling Methods 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 239000002390 adhesive tape Substances 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 238000001502 gel electrophoresis Methods 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 239000011534 wash buffer Substances 0.000 description 9
- 229920001410 Microfiber Polymers 0.000 description 8
- 239000012148 binding buffer Substances 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 238000010790 dilution Methods 0.000 description 8
- 239000012895 dilution Substances 0.000 description 8
- 239000000499 gel Substances 0.000 description 8
- 239000011521 glass Substances 0.000 description 8
- 239000012139 lysis buffer Substances 0.000 description 8
- 239000003658 microfiber Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 210000003296 saliva Anatomy 0.000 description 8
- 230000004544 DNA amplification Effects 0.000 description 7
- 239000013614 RNA sample Substances 0.000 description 7
- 208000001455 Zika Virus Infection Diseases 0.000 description 7
- 208000035332 Zika virus disease Diseases 0.000 description 7
- 230000005540 biological transmission Effects 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 230000009089 cytolysis Effects 0.000 description 7
- 230000000120 cytopathologic effect Effects 0.000 description 7
- 239000010408 film Substances 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 206010022000 influenza Diseases 0.000 description 7
- 238000003475 lamination Methods 0.000 description 7
- 239000006166 lysate Substances 0.000 description 7
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- 229940098773 bovine serum albumin Drugs 0.000 description 6
- 229920002678 cellulose Polymers 0.000 description 6
- 239000001913 cellulose Substances 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 238000003752 polymerase chain reaction Methods 0.000 description 6
- 239000000377 silicon dioxide Substances 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 4
- 208000035473 Communicable disease Diseases 0.000 description 4
- 102100034343 Integrase Human genes 0.000 description 4
- MQUQNUAYKLCRME-INIZCTEOSA-N N-tosyl-L-phenylalanyl chloromethyl ketone Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N[C@H](C(=O)CCl)CC1=CC=CC=C1 MQUQNUAYKLCRME-INIZCTEOSA-N 0.000 description 4
- 239000004372 Polyvinyl alcohol Substances 0.000 description 4
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 4
- -1 SYBR green I nucleic acid Chemical class 0.000 description 4
- 102000006943 Uracil-DNA Glycosidase Human genes 0.000 description 4
- 108010072685 Uracil-DNA Glycosidase Proteins 0.000 description 4
- 201000004296 Zika fever Diseases 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 238000005520 cutting process Methods 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 241001493065 dsRNA viruses Species 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 238000003757 reverse transcription PCR Methods 0.000 description 4
- 229920000936 Agarose Polymers 0.000 description 3
- 241000450599 DNA viruses Species 0.000 description 3
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 3
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 238000007397 LAMP assay Methods 0.000 description 3
- 230000004570 RNA-binding Effects 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 238000000246 agarose gel electrophoresis Methods 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 239000001046 green dye Substances 0.000 description 3
- 238000011901 isothermal amplification Methods 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 238000003801 milling Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000005096 rolling process Methods 0.000 description 3
- 239000002356 single layer Substances 0.000 description 3
- 238000012421 spiking Methods 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 229920001169 thermoplastic Polymers 0.000 description 3
- 239000004416 thermosoftening plastic Substances 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 238000010146 3D printing Methods 0.000 description 2
- 208000025721 COVID-19 Diseases 0.000 description 2
- 241001167556 Catena Species 0.000 description 2
- 229920003043 Cellulose fiber Polymers 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000710831 Flavivirus Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- OAZWDJGLIYNYMU-UHFFFAOYSA-N Leucocrystal Violet Chemical compound C1=CC(N(C)C)=CC=C1C(C=1C=CC(=CC=1)N(C)C)C1=CC=C(N(C)C)C=C1 OAZWDJGLIYNYMU-UHFFFAOYSA-N 0.000 description 2
- 108060004795 Methyltransferase Proteins 0.000 description 2
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 229910000831 Steel Inorganic materials 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000001985 kidney epithelial cell Anatomy 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000003754 machining Methods 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 238000001821 nucleic acid purification Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 239000004626 polylactic acid Substances 0.000 description 2
- 239000011535 reaction buffer Substances 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 239000010959 steel Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- AUIINJJXRXMPGT-UHFFFAOYSA-K trisodium 3-hydroxy-4-[(2-hydroxy-4-sulfonatonaphthalen-1-yl)diazenyl]naphthalene-2,7-disulfonate Chemical compound [Na+].[Na+].[Na+].Oc1cc(c2ccccc2c1N=Nc1c(O)c(cc2cc(ccc12)S([O-])(=O)=O)S([O-])(=O)=O)S([O-])(=O)=O AUIINJJXRXMPGT-UHFFFAOYSA-K 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- MFYSUUPKMDJYPF-UHFFFAOYSA-N 2-[(4-methyl-2-nitrophenyl)diazenyl]-3-oxo-n-phenylbutanamide Chemical compound C=1C=CC=CC=1NC(=O)C(C(=O)C)N=NC1=CC=C(C)C=C1[N+]([O-])=O MFYSUUPKMDJYPF-UHFFFAOYSA-N 0.000 description 1
- 101100272788 Arabidopsis thaliana BSL3 gene Proteins 0.000 description 1
- 241000203069 Archaea Species 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 101150011571 BSL2 gene Proteins 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 208000001490 Dengue Diseases 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 241000710781 Flaviviridae Species 0.000 description 1
- 206010054261 Flavivirus infection Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241001500351 Influenzavirus A Species 0.000 description 1
- 241000880493 Leptailurus serval Species 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 101150001779 ORF1a gene Proteins 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 102000018120 Recombinases Human genes 0.000 description 1
- 108010091086 Recombinases Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 101150010882 S gene Proteins 0.000 description 1
- 235000017276 Salvia Nutrition 0.000 description 1
- 240000007164 Salvia officinalis Species 0.000 description 1
- ILVGMCVCQBJPSH-WDSKDSINSA-N Ser-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CO ILVGMCVCQBJPSH-WDSKDSINSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 208000011312 Vector Borne disease Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 244000000022 airborne pathogen Species 0.000 description 1
- 229960002648 alanylglutamine Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229910052681 coesite Inorganic materials 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000009351 contact transmission Effects 0.000 description 1
- 239000013039 cover film Substances 0.000 description 1
- 229910052906 cristobalite Inorganic materials 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 208000025729 dengue disease Diseases 0.000 description 1
- 230000010460 detection of virus Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 238000001746 injection moulding Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000005541 medical transmission Effects 0.000 description 1
- 208000004141 microcephaly Diseases 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 229920006255 plastic film Polymers 0.000 description 1
- 229920006289 polycarbonate film Polymers 0.000 description 1
- 238000012809 post-inoculation Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011897 real-time detection Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000010832 regulated medical waste Substances 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229910052682 stishovite Inorganic materials 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229910052905 tridymite Inorganic materials 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 230000002477 vacuolizing effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M41/00—Means for regulation, monitoring, measurement or control, e.g. flow regulation
- C12M41/46—Means for regulation, monitoring, measurement or control, e.g. flow regulation of cellular or enzymatic activity or functionality, e.g. cell viability
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/52—Containers specially adapted for storing or dispensing a reagent
- B01L3/527—Containers specially adapted for storing or dispensing a reagent for a plurality of reagents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M23/00—Constructional details, e.g. recesses, hinges
- C12M23/44—Multiple separable units; Modules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M41/00—Means for regulation, monitoring, measurement or control, e.g. flow regulation
- C12M41/48—Automatic or computerized control
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/56916—Enterobacteria, e.g. shigella, salmonella, klebsiella, serratia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
- B01L2200/02—Adapting objects or devices to another
- B01L2200/025—Align devices or objects to ensure defined positions relative to each other
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
- B01L2200/02—Adapting objects or devices to another
- B01L2200/026—Fluid interfacing between devices or objects, e.g. connectors, inlet details
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
- B01L2200/02—Adapting objects or devices to another
- B01L2200/028—Modular arrangements
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0809—Geometry, shape and general structure rectangular shaped
- B01L2300/0829—Multi-well plates; Microtitration plates
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2400/00—Moving or stopping fluids
- B01L2400/06—Valves, specific forms thereof
- B01L2400/0605—Valves, specific forms thereof check valves
- B01L2400/0616—Ball valves
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/702—Specific hybridization probes for retroviruses
Definitions
- sequence identifier numbers correspond numerically to the sequence identifiers ⁇ 400>1, ⁇ 400>2, etc.
- sequence listing in written computer readable format is submitted Apr. 19, 2021, as a text file named “222107-1315 Sequence Listing ST25.txt” created on Apr. 19, 2021, and has a size of 15,114 bytes.
- This invention was created in part by funding received from Grant No. 7ZK22 of the Zika Research Grant Initiative Project awarded by the Florida Department of Health, Biomedical Research Program, for The State of Florida.
- This present disclosure relates to methods and apparatuses for detecting microorganisms.
- Zika virus is a mosquito-borne flavivirus (family Flaviviridae) that caused epidemics in Brazil in 2015 and spread quickly into the United States.
- the Zika virus disease became a nationally notifiable condition in 2016.
- Zika virus was first isolated from a non-human primate in 1947 in Africa.
- Zika virus infections in humans were sporadic before the first outbreak in 2007 and thought to be mainly asymptomatic, some causing dengue-like symptoms such as fever, headache, rash, arthralgia, myalgia and conjunctivitis. Since the French Polynesian outbreak in 2013, however, Zika virus disease has been associated with severe neurological complications, including Guillain-Barré syndrome (GBS) in adults and microcephaly in neonates.
- GBS Guillain-Barré syndrome
- the U.S. Centers for Disease Control and Prevention recommend Zika virus RNA nucleic acid testing (NAT) and Zika virus and/or dengue virus IgM testing for symptomatic patients with possible Zika exposure.
- serological testing by IgM and IgG enzyme-linked immunosorbent assay (ELISA) or lateral flow assay (LFA) is often performed for the rapid diagnosis of similar flavivirus infections.
- ELISA enzyme-linked immunosorbent assay
- LFA lateral flow assay
- NAT such as reverse transcription polymerase chain reaction (RT-PCR) or reverse transcription loop-mediated isothermal amplification (RT-LAMP) is highly recommended when detecting Zika virus infection, especially for developing a point-of-care (POC) test for resource-limited regions.
- RT-PCR reverse transcription polymerase chain reaction
- R-LAMP reverse transcription loop-mediated isothermal amplification
- NAT can be PCR or LAMP.
- E. coli Escherichia coli
- NAT is PCR or LAMP.
- LAMP or RT-LAMP can also be replaced with other isothermal application methods including rolling circle amplification (RCA), helicase-dependent amplification (HDA), recombinase polymerase amplification (RPA), nucleic acid sequence-based amplification (NASBA), and others.
- RCA rolling circle amplification
- HDA helicase-dependent amplification
- RPA recombinase polymerase amplification
- NASBA nucleic acid sequence-based amplification
- RT-LAMP has been extensively used as a NAT for POC RNA virus detection system due to its robustness, high sensitivity and specificity, short incubation time, simplified thermal management and instrument-free product detection. Since the outbreak of Zika virus in 2013, a lot of RT-LAMP tests have been developed to specifically detect Zika virus RNA, some of which even have the ability to differentiate between Asian and African Zika linage.
- RNA extraction methods such as the organic extraction method and the solid phase extraction (SPE) method are often time-consuming and labor-intensive.
- SPE solid phase extraction
- the requirement for centrifugation equipment, various kinds of reagents and a controlled environment often makes it unrealistic for most circumstances outside of a lab.
- microfluidic NAT devices have been developed for POC testing employing the SPE technique, incorporating elements such as silicon micropillars, silica monolith, SiO 2 coating, packed silica beads and paramagnetic silica particles in microchannels. These devices, however, are expensive to make and often require lab instruments (e.g. syringe pump) to operate.
- Airborne infectious reagents such as influenza viruses, coronaviruses, rhinoviruses and adenoviruses
- Understanding the aerosol transmission mode is of great importance, as the risk of respiratory disease transmission through this route is exceptionally high in population-dense areas, such as schools, hospitals, airports and industrial animal farms.
- the relative importance of the aerosol transmission route among the three is controversial, due to the limitations in the sampling and detection methods available for small-sized virus aerosols.
- traditional methods used to detect the collected virus aerosols for example, viral culture and polymerase chain reactions (PCR), are time-consuming and labor-intensive. The requirements of well-equipped lab and highly-trained personnel often make it unrealistic in resource-limited settings.
- VIVAS Viable Virus Aerosol Sampler
- the VIVAS has been successfully used to collect a variety of viable human respiratory viruses in a student infirmary of the University of Florida during a late-onset 2016 influenza virus outbreak as well as coronavirus disease 2019 (COVID-19).
- the high collection efficiency with the proven ability to collect real-world virus aerosols makes the VIVAS highly suitable for becoming a part of sample-to-answer virus aerosol detector.
- An ideal sample-to-answer virus aerosol detection system includes an efficient aerosols collector and a rapid, sensitive detector for the collected virus. Moreover, these two components should be integrated in a way to operate without manual steps or with the minimum amount of manual interventions. Rapid enzyme immunoassay-based POC testing for human respiratory diseases such as the QuickVue Influenza A+B Test has been available in hospitals for serval years. However, the enzyme immunoassay-based POC testing has lower sensitivities compared to NAT.
- FIGS. 1A-1E illustrates various aspects of the apparatus for detecting microorganisms in accordance with a representative embodiment.
- FIGS. 2A-2F illustrate the method for detecting microorganisms using the apparatus shown in FIGS. 1A-1E .
- FIGS. 3A-3E show photographs of the apparatus shown in FIGS. 1A-1E and the VIVAS that is used to collect the sample.
- FIG. 4A is a graph showing curves representing normalized fluorescent signals of 10, 100, and 1000 TCID 50 H1N1 flu virus genome equivalents as a function of RT-LAMP time; the curves indicate that all samples' amplification signals reached the plateau in 20 minutes.
- FIG. 4B is a standard curve (log TCID 50 per reaction vs. threshold time) generated with three replicates of each serial diluted H1N1 flu virus RNA samples.
- FIGS. 5A-5C are photographs showing how 1 TCID 50 H1N1 flu virus per 140 sample was successfully detected in one hour using the apparatus shown in FIGS. 1A-1E .
- FIGS. 6A-6C are photographs showing how the apparatus shown in FIGS. 1A-1E was used to successfully detect the H1N1 flu virus aerosols generated in a lab.
- FIGS. 7A-7D are perspective views of the apparatus and components thereof in accordance with another representative embodiment.
- FIGS. 8A-8C are photographs of the apparatus shown in FIGS. 7A-7D .
- FIGS. 9A-9F illustrate the method for detecting microorganisms using the apparatus shown in FIGS. 7A-7D .
- FIG. 10A depicts curves representing normalized fluorescent signals of 5, 50, and 500 PFU Zika virus genome equivalents amplification by RT-LAMP showing that all samples' amplification signals reached the plateau in 20 min.
- FIG. 10B depicts a standard curve (log PFU per reaction vs. threshold time) generated with 3 replicates of each serial diluted Zika virus RNA samples.
- FIG. 11A is a photograph of the detection unit of the apparatus shown in FIGS. 7A-7D corresponding to the results under ambient light.
- FIG. 11B is a photograph of the detection unit of the apparatus shown in FIGS. 7A-7D corresponding to the results under light from a blue LED flashlight.
- FIG. 11C is a gel electrophoresis image of the amplicons from each device; from left lane to right: 100 by DNA marker, 1, 0.5, 0.1 PFU and NTC.
- FIGS. 12A and 12B are photographs of the detection unit of the apparatus shown in FIGS. 7A-7D under ambient light and light from a blue LED flashlight, respectively; P is the positive control S is a clinical sample, and NTC is no-template control.
- FIG. 12C is a gel electrophoresis image of the amplicons from each detection unit.
- FIG. 13A is a photograph showing Zika virus detection using the detection unit of the apparatus shown in FIGS. 7A-7D incubated in the EmberTM travel mug and analyzed under ambient light.
- FIG. 13B is a photograph showing Zika virus detection using the detection unit of the apparatus shown in FIGS. 7A-7D incubated in the EmberTM travel mug and analyzed under light from a blue LED flashlight.
- FIG. 13C is a gel electrophoresis image of the amplicons from each detection unit; from left lane to right: 100 bp DNA marker, 100, 10, 1 PFU and NTC.
- FIG. 13D is a photograph showing detection units submerged in water in an EmberTM travel mug.
- FIG. 14 is a plot of a temperature calibration curve 140 for calibrating the EmberTM mug shown in FIG. 13D .
- FIGS. 15A and 15B are photographs showing detection results under ambient light and blue LED flashlight, respectively, obtained by the apparatus 20 shown in FIGS. 7C and 9A-9F for detection of 14 ⁇ l of ZIKV-spiked urine samples.
- FIG. 16 is a flow diagram representing the method in accordance with a representative embodiment for preparing a sample for use in detecting microorganisms.
- FIGS. 17A-17D are images depicting sensitivity tests for the SARS-CoV-2 RT-LAMP assay, incubating at 62.5° C. for 25 min for results obtained using the method and apparatus described with reference to FIGS. 7A-7C .
- the present disclosure discloses an apparatus and a method for performing microorganism detection.
- the apparatus is capable of detecting microorganisms (e.g., viruses) with high sensitivity, is well suited for POC testing in resource-limited regions and is capable of being operated with very little manual intervention and without the need for lab equipment.
- a collector unit of the apparatus comprises at least a first reservoir for holding at least a first liquid sample.
- a buffer unit of the apparatus includes at least second, third and fourth reservoirs for holding at least second, third and fourth liquids, respectively.
- a mechanical coupling mechanism of the apparatus couples the collector unit and the buffer unit together in a manner that allows a user to create relative movement between the collector unit and the buffer unit by exerting a force on at least one of the buffer unit and the collector unit.
- a valve mechanism of the apparatus causes the second, third and fourth liquids to be released from the second, third and fourth reservoirs, respectively, into the first reservoir, in turn, when the user creates relative movement between the collector unit and the buffer unit to cause the second, third and fourth reservoirs to come into temporary alignment with the first reservoir for respective time periods.
- a detection unit of the apparatus that is removably coupled to the collector unit receives liquid from the first reservoir. The detection unit can be removed from the collector unit and analyzed to determine whether the liquid received by the detection unit contains a particular microorganism.
- a device includes one device and plural devices.
- the terms “substantial” or “substantially” mean to within acceptable limits or degrees acceptable to those of skill in the art.
- substantially parallel to means that a structure or device may not be made perfectly parallel to some other structure or device due to tolerances or imperfections in the process by which the structures or devices are made.
- approximately means to within an acceptable limit or amount to one of ordinary skill in the art.
- Relative terms such as “over,” “above,” “below,” “top,” “bottom,” “upper” and “lower” may be used to describe the various elements' relationships to one another, as illustrated in the accompanying drawings. These relative terms are intended to encompass different orientations of the device and/or elements in addition to the orientation depicted in the drawings. For example, if the device were inverted with respect to the view in the drawings, an element described as “above” another element, for example, would now be below that element.
- microorganism refers to a small (often, but not always, microscopic) organism that is typically, but not exclusively, single cellular, and includes organisms from the kingdoms bacteria, archaea, protozoa, and fungi. Viruses are also classified as microorganisms in the present disclosure document even though they are not living organisms by themselves.
- the apparatus and method will first be described with reference to a representative embodiment for performing airborne virus detection in an example application in which the virus being detected is influenza. The apparatus and method will then be described with reference to a representative embodiment for detecting non-airborne viruses in an example application in which the virus being detected is the Zika virus. Data is also disclosed herein of experiments that were conducted using the method and apparatus to detect coronaviruses, and in particular, SARS-CoV-2. All of the representative embodiments described herein are capable of being implemented as portable, rapid, reliable and cost-effective diagnostic POC tools that can be operated without the need for lab equipment and with very little human intervention. Accordingly, the apparatuses and methods are well suited for, but not limited to, use in resource-limited regions.
- the aerosol transmission route is one of the three major transmission routes of airborne infectious diseases.
- the dynamics and significance of the aerosol transmission route are not well understood, nor does there exist an automatic, efficient and realistic biosensor for detecting small-sized virus aerosols.
- the assignee's VIVAS is a water-vapor-based condensational growth system capable of collecting aerosolized particles (e.g., from 8 nm to 10 ⁇ m in size).
- the apparatus includes 3D-printed sample preparation components and a laminated paper-based RNA amplification component, referred to hereinafter collectively as the “SPRA” apparatus.
- the SPRA apparatus is designed to integrate with the VIVAS to perform a rapid, sample-to-answer virus aerosol detection based on the RT-LAMP.
- the integrated SPRA apparatus and VIVAS is referred to hereinafter as the “integrated SPRA-VIVAS platform.”
- the 3D-printed sample preparation component of the SPRA apparatus includes an innovative “bearing ball valve” capable of storing and delivering reagents without manually pipetting.
- the inventors have tested the sensitivity of the SPRA apparatus to detect 1 TCID 50 H1N1 flu viruses spiked in 140 ⁇ L aqueous sample, which is more sensitive than the commercial FTA® card and WhatmanTM glass microfiber.
- the inventors Using the integrated SPRA-VIVAS platform, the inventors have demonstrated the successful detection of lab-generated H1N1 flu virus aerosols in less than one hour.
- the results demonstrate that the SPRA-VIVAS platform has a great potential in airborne infectious disease screening and monitoring during outbreaks.
- the effective sampling and rapid detection of virus aerosols also facilitates a better understanding of the significance of aerosol transmission mode in airborne infectious disease outbreaks.
- the RT-LAMP is integrated with the VIVAS, with the RT-LAMP being used to detect the virus aerosols that are collected by the VIVAS.
- the RT-LAMP is an isothermal DNA amplification technique with high robustness, sensitivity and specificity. With its short incubation time and simplified thermal management, RT-LAMP can be easily employed by POC platforms.
- a laminated paper-based device is used for extraction. Compared to analytical devices made of other materials, paper-based devices have the advantages of being extremely low-cost, flexible, easy to dispose and capable of pumping liquid using capillary forces.
- 3D-printed components are used to house the laminated paper-based device and the RNA extraction reagents.
- an innovative valving mechanism inspired by the small animal water bottle is employed to conduct RNA extraction without the help of even basic lab equipment such as a pipette.
- the 3D-printed components allow the laminated paper-based device to be combined with the VIVAS, so that the aerosols collected by the VIVAS can be directly impinged onto the RNA extraction pad.
- FIGS. 1A-1E illustrate top perspective views of the SPRA apparatus 1 in accordance with a representative embodiment in its partially-disassembled state to reveal features of the various components of the SPRA apparatus 1 that would not be visible in the fully-assembled state.
- FIG. 1A shows the detection unit 2 , which, in accordance with this representative embodiment, is a laminated paper-based RNA amplification device referred to hereinafter as “the paper-based RNA amplification device 2 .”
- a paper pad 2 a of the device 2 is laminated between two layers of thermoplastic films 2 b and 2 c of the device 2 in the manner in which a common identification card is fabricated.
- FIG. 1A shows the detection unit 2 , which, in accordance with this representative embodiment, is a laminated paper-based RNA amplification device referred to hereinafter as “the paper-based RNA amplification device 2 .”
- a paper pad 2 a of the device 2 is laminated between two layers of thermoplastic films 2 b and 2 c of the
- FIG. 1B shows the paper-based RNA amplification device 2 attached to a polycarbonate container 3 via an adhesive tape 4 .
- FIG. 1C shows a cross-sectional side view of the mechanism of the bearing ball valve 5 of the SPRA rotatable reservoir unit 6 .
- the valve 5 is actuated by a pillar 7 of the SPRA collector 8 pushing the bearing ball 9 up to discharge the liquid housed in the reservoir.
- FIG. 1D shows the SPRA apparatus 1 , which includes the SPRA collector 8 and a buffer unit 6 .
- the buffer unit 6 is a rotatable buffer unit referred to hereinafter as “the SPRA rotatable reservoir unit 6 .”
- the SPRA rotatable reservoir unit 6 and the SPRA collector unit 8 are assembled together via a pin 11 .
- the SPRA rotatable reservoir unit 6 is rotatably coupled to the SPRA collector 8 .
- the rotatable SPRA reservoir unit 6 includes three reservoirs to separately house the binding buffer and the two wash buffers.
- the SPRA collector 8 functions as a sample collector with the laminated paper-based RNA amplification device 2 attached underneath.
- FIG. 1E shows a lure-lock-threaded lid 13 of the SPRA rotatable reservoir unit 6 with an O-ring used to prevent liquid leakage during transportation. A protruded peg underneath the lid 13 is designed to press down the bearing ball once the lid 13 is tightened, as will be described below in more detail.
- lids 13 of different sizes are used to seal the binding buffer 6 a and the two wash buffers 6 b and 6 c of the SPRA rotatable reservoir unit 6 to prevent spillage during transportation.
- the design can be the same for all of the lids, but lids of the wash buffers 6 b and 6 c are smaller in diameter than the lid of the binding buffer 6 a . Securing the lids to the respective buffers 6 a - 6 c causes the ball bearing valves of the buffers 6 a - 6 c to be locked in the closed positions.
- FIGS. 2A-2F are top perspective views of the SPRA apparatus 1 and the VIVAS 12 at various stages during use.
- the SPRA collector 8 is mechanically coupled to the bottom of the VIVAS 12 by a 3D-printed device holder 14 .
- the detection scheme for viruses collected from aerosols is as follows. The virus particles in the aerosol are enlarged by the VIVAS 12 and impinged directly into the lysis buffer housed in the reservoir of the SPRA collector 8 , as shown in FIG. 2A . After a 15-minute collection period, the SPRA collector 8 was removed from the VIVAS 12 and assembled with the rotatable SPRA reservoir unit 6 , as shown in FIG. 2B .
- the rotatable SPRA reservoir unit 6 was then rotated to discharge the binding buffer 6 a into the virus lysate held in the SPRA collector 8 .
- the laminated paper-based RNA amplification device 2 underneath the SPRA collector 8 filtered the virus RNA from the lysate.
- the rotatable SPRA reservoir unit 6 was rotated to discharge the two wash buffers 6 b and 6 c sequentially, as indicated by FIGS. 2C and 2D .
- the whole RNA purification process took around 25 minutes, depending on the collected volume.
- the laminated paper-based RNA amplification device 2 was then peeled from the collector 8 and taped onto the polycarbonate container 3 for RT-LAMP amplification. After a 25-minute incubation period, as depicted in FIG. 2E , the amplified DNA could be detected using 1 ⁇ L SYBR Green dye and a blue LED flashlight, as shown in FIG. 2F .
- FIG. 3A shows a top-view photograph of the rotatable SPRA reservoir unit 6 shown in FIGS. 1D and 1E .
- FIG. 3B shows top-view and bottom-view photographs of the rotatable SPRA reservoir unit 6 with the lids 13 attached to the respective buffers 6 a - 6 c .
- FIG. 3C shows a side-view photograph of the VIVAS 12 having the device holder 14 ( FIG. 2A ) mechanically coupled to the bottom of the VIVAS 12 .
- the device holder 14 couples the SPRA collector 8 to the VIVAS 12 .
- FIG. 3D shows a top-view photograph of the device holder 14 holding the SPRA collector 8 .
- FIG. 3E shows a bottom-view photograph of the device holder 14 .
- MDCK CCL-34; Madin-Darby Canine Kidney Epithelial Cells
- MDCK CCL-34; Madin-Darby Canine Kidney Epithelial Cells
- aDMEM Advanced Dulbecco's Modified Eagle's Medium
- GlutaMAX 2 mM L-Alanyl-L-Glutamine
- PSN 50 ⁇ g/mL penicillin, 50 ⁇ g/mL streptomycin, 100 ⁇ g/mL neomycin (Invitrogen)
- 10% (v/v) low IgG, heat-inactivated gamma-irradiated fetal bovine serum HyClone, Logan, Utah.
- TPCK trypsin was used at a final concentration of 2 ⁇ g/mL for MDCK. After 4 hours of incubation, 3 mL of serum-free aDMEM supplemented with TPCK trypsin was added. After CPE were observed in over 50% of cells, the cells were scraped, and the virus was collected and frozen at ⁇ 80° C. A virus stock solution of 6.4 ⁇ 10 6 TCID 50 /mL was used for sample spiking and RNA extraction.
- RT-LAMP reverse transcriptase loop-mediated isothermal amplification
- Each 25 ⁇ L RT-LAMP system contains 2.5 ⁇ L of 10 ⁇ isothermal amplification buffer, 1.4 mM dNTPs, 6 mM MgSO 4 , 2.5 of 10 ⁇ primer mix, 8 U Bst 2.0 WarmStart® DNA Polymerase, 7.5 U WarmStart® RTx Reverse Transcriptase, and 1 ⁇ L RNA sample. Except for the dNTPs from ThermoFisher Scientific (MA, USA), other reagents in the RT-LAMP system was obtained from New England Biolabs (Ipswich, Mass., USA). The primer mix contains 1.6 ⁇ M F1P/B1P, 0.2 F3/B3, and 0.4 ⁇ M LF/LB.
- a real-time RT-LAMP assay was carried out.
- 0.5 of 10 ⁇ concentrate SYBR green I nucleic acid gel stain in DMSO (ThermoFisher Scientific) and 0.5 ⁇ L ROX reference dye (ThermoFisher Scientific) were added to the 25 ⁇ L RT-LAMP reaction buffer.
- the fluorescence signal was read through the QuantStudio 3 real-time PCR system (ThermoFisher Scientific).
- the laminated paper-based RNA amplification device 2 ( FIGS. 1A and 1B ) contains a polycarbonate container, a double-sided adhesive tape, and a laminated paper pad.
- a 3.5-mm-diameter round pad of the paper material was made using a steel puncher.
- thermoplastic films Two layers of thermoplastic films were shaped by cutting a section of 75 ⁇ m thick polyester thermal bonding lamination films (Lamination Plus, Kaysville, Utah, USA) using a Graphtec Craft Robo-S cutting plotter (Graphtec Corporation, Yokohama, Japan).
- the paper pad and the top and bottom films were aligned and passed through a heated laminator (GBC® Catena 65 Roll Laminator, GBC, Lake Zurich, Ill., USA), which was set at a rolling speed of “1” with the temperature at 220 T.
- GBC® Catena 65 Roll Laminator GBC, Lake Zurich, Ill., USA
- the laminated paper pad was attached to a 3 mm thick, 2 cm ⁇ 2 cm square polycarbonate container via a piece of 3M 9087 white bonding tape (R. S.
- the container was shaped from a piece of clear polycarbonate sheet (McMaster-Carr, Elmhurst, Ill.) using a milling machine (Sherline Products, Vista, Calif.). A 3-mm-diameter round hole was made in both the polycarbonate container and the double-sided adhesive tape to align with the paper pad as a sample loading port.
- the lysis product mixture of H1N1 flu virus was used to test the performance of laminated paper-based RNA amplification device. Aliquots containing 10, 1, and 0.1 TCID 50 H1N1 flu virus lysis per ⁇ L were made with the flu virus stock solution and molecular-biology-grade water and buffer AVL (QIAGEN) at the ratio of 1:4 and stored at ⁇ 80° C. before use.
- RNA capture efficiency of laminated paper-based RNA amplification device made of FTA® card, chromatography paper and glass microfiber paper a series dilution of 70 ⁇ L H1N1 flu virus lysis (made from virus spiked water and AVL lysis buffer in the ratio of 1:4) was used to compare the limit of detection (LOD) of each material.
- An ethanol (200 proof) solution of 56 ⁇ L was mixed into the diluted virus lysis before introducing to the device.
- a solution of 100 ⁇ L each AW1 (QIAGEN) and AW2 (QIAGEN) of 100 ⁇ L each was then filtered through the paper pad sequentially to purify the RNA captured by the device.
- RNA RNA was captured using a piece of adhesive tape (Fellows)° 4 ( FIG. 1B ) was attached to the bottom of the device 2 ( FIGS. 1A and 1B ), and 25 ⁇ L RT-LAMP amplification buffer was loaded to the paper pad.
- the device 2 was then sealed with another piece of adhesive tape on the top.
- the sealed device was incubated at 63° C. for 25 minutes in an Isotemp 105 water bath (ThermoFisher Scientific) for DNA amplification.
- the amplicons were analyzed with gel electrophoresis as described above.
- 3D-printed sample preparation components were designed to incorporate the laminated paper-based RNA amplification device 2 to form the final SPRA apparatus 6 . These components could be used to perform viral RNA purification without using lab tools such as a pipette, for example.
- the sample preparation components were fabricated with a commercial 3D printer, Ultimaker 3 (Ultimaker, Geldermalsen, Netherlands), using polylactic acid (PLA) filament with polyvinyl alcohol (PVA) as support material.
- PLA polylactic acid
- PVA polyvinyl alcohol
- the print layer height was set to 0.06 mm and the infill density was set to 100%.
- the 3D-printed sample preparation components contain two units.
- the SPRA rotatable reservoir unit 6 comprises the buffer reservoir 6 a housing the binding buffer (molecular-biology grade ethanol) and the two wash buffers (AW1 & AW2, QIAGEN) 6 b and 6 c for RNA purification.
- the bottom unit of the SPRA apparatus 1 is the aforementioned SPRA collector 8 where the laminated paper-based RNA amplification device 2 was attached with a piece of double-sided tape.
- the SPRA apparatus 1 was assembled by inserting the pin 11 through one hole located in each unit.
- a photo of the SPRA apparatus 1 compared to a U.S. quarter is shown in FIG. 3A .
- a simple fluid control valve the “bearing ball” valve shown in FIG. 1C , was employed to trigger the release of buffers from the buffer reservoirs 6 a - 6 c to the SPRA collector 8 of the SPRA apparatus 1 .
- the valve was inspired by the small animal water bottle in which water flowed out when a drinking animal pressed against the bearing ball blocking the water dispensing tube.
- a 5/16-inch-diameter opening was designed at the bottom of the funnel-shaped reservoirs 6 a - 6 c to house a stainless-steel bearing ball 9 .
- the opening was designed in such a way that the bearing ball could block the opening while protruding 2 mm from the bottom of the buffer reservoir.
- the bearing ball 9 functioned as a plug to keep the liquid from flowing out.
- the bearing ball valve could be triggered by rotating the reservoir unit until the ball was pushed up by a pillar 7 ( FIG. 1D ) in the center of the collector 8 .
- the lid 13 FIGS. 1E and 3B with a lure-lock thread and a piece of O-ring (McMaster-Carr) was used.
- the lid 13 contained a peg underneath that pressed against the bearing ball 9 while the thread was tightened.
- the lid 13 achieved a leak-free seal when the device was rotated upside down.
- H1N1 flu virus was used for virus aerosol generation and testing. All the sampling experiments were performed in a US Department of Agriculture inspected-and-approved BSL2-enhanced laboratory following BSL3 work practices.
- 10 mL of 1 ⁇ 10 5 TCID 50 /mL H1N1 flu virus solution in phosphate-buffered saline (PBS) plus 0.5% (w/v) bovine serum albumin (BSA) fraction V was used with a 6-jet BioAerosol Nebulizing Generator (BANG, CH Technologies). 25-27 HEPA-filtered room air was used to provide air flow for the BANG.
- PBS phosphate-buffered saline
- BSA bovine serum albumin
- the VIVAS 12 ( FIGS. 2A and 3C ), a laminar-flow, water-based condensational growth system, was used to amplify the virus aerosols generated by the BANG and has been described previously.
- the device holder 14 was designed to fixate, or mechanically couple, the SPRA collector 8 to the VIVAS' aerosol outlet with four screws.
- a rubber pad was used to form an air-tight seal to prevent aerosol leakage during sampling ( FIG. 3C ).
- Fluorescein aerosols were used to demonstrate the collection result. As shown in FIG. 3E , the collected droplets deposited by the 32 nozzles of the VIVAS could be observed in the SPRA collector 8 .
- the conditioner (the top half) of the VIVAS 12 was cooled to 6° C., and the initiator (the bottom half) was heated to 45° C.
- An air flow rate at six liters per minute (LPM) was introduced into the VIVAS 12 .
- a negative control sample was first collected with 10 mL PBS plus 0.5% (w/v) BSA in the BANG for 15 minutes. Three positive collections with virus solution in the BANG were performed for 15 minutes each.
- a lysis buffer (buffer AVL) of 560 ⁇ L was preloaded to the SPRA collector 8 where the aerosols from the VIVAS 12 directly impinged. The lysis buffer protected viral RNA from RNase degradation and deactivated the collected virus to reduce the generation of biohazardous wastes.
- a washing step consisting of 5-minute collection of 0.01% sodium dodecyl sulfate (SDS, ThermoFisher Scientific) solution in the BANG and then 25-minute collection of molecular-biology grade water in BANG was performed to flush the virus aerosols in the system from a previous sampling.
- SDS sodium dodecyl sulfate
- the SPRA collector was removed from the VIVAS 12 by loosening screws and assembled with the top reservoir unit 6 ( FIG. 1D ).
- the assembled SPRA apparatus 1 was first placed on top of a piece of blotting paper to provide capillary forces for the RNA purification process.
- the binding buffer 6 a (560 ⁇ L ethanol) was discharged right after to enhance RNA binding to the laminated paper pad. The blotting process took roughly 15 minutes, depending on the volume of sample collected and the type of absorbent used.
- the reservoir unit 6 of the SPRA apparatus 1 was rotated to add the first wash buffer 6 b (250 AW1) to the collector 8 , and the top reservoir unit 6 was rotated again, and the second wash buffer 6 c (250 ⁇ L AW2) was discharged and filtered through in the same manner.
- the two wash steps took roughly 5 minutes to complete.
- the laminated paper-based RNA amplification device 2 was peeled from the SPRA collector 8 and taped to its polycarbonate container 3 ( FIG. 1B ) to conduct RT-LAMP amplification as described previously. After 25 minutes incubation, 1 ⁇ L of 10,000 ⁇ concentrate SYBR green I nucleic acid gel stain was added to the amplicons, and the results can be read by a naked-eye.
- an ULAKO blue LED flashlight (Amazon, Wash., USA) ( FIG. 2F ) powered by an AA battery was used to excite the green fluorescence from the amplicon-SYBR complexes. The resulting color of the solution was imaged using a smart phone.
- a piece of brown-tainted translucent plastic film was taped in front of the phone camera lens to filter out the excess blue light from the LED flashlight. It should be noted that other light sources such as lamps and various diodes, for example, can be used for this purpose, as will be understood by those of skill in the art in view of the description provided herein.
- FIG. 4A is a graph showing curves 16 , 17 , 18 and 19 representing normalized fluorescent signals of 10, 100, 1000 and no-temperature control (NTC), respectively, TCID 50 H1N1 flu virus genome equivalents as a function of RT-LAMP time.
- the curves 16 - 19 indicate that all samples' amplification signals reached the plateau in 20 minutes.
- FIG. 4B is a plot of a standard curve (log TCID 50 per reaction vs. threshold time) generated with three replicates of each serial diluted H1N1 flu virus RNA samples.
- the QIAamp Viral RNA Mini Kit (QIAGEN) was used as a bench top standard to purify RNA from aqueous samples spiked with H1N1 flu virus.
- Fluorescence readings were taken from RT-LAMP containing 10, 100 an(a) d 1000 TCID 50 RNA equivalents using the QuantStudio 3 real-time PCR system ( FIG. 4A ). All the wells containing flu virus RNA were observed with a signal within 20 minutes, and no non-specific amplification was observed during the 30-minute incubation period. This result suggested that a 25-minute incubation was sufficient to detect the flu virus RNA isolated by our device.
- the linear-shaped standard curve ( FIG. 4B ) indicated that quantitative virus aerosol detection can be achieved by the integrated SPRA-VIVAS platform with portable optical sensors.
- the laminated paper-based RNA amplification device 2 used in the experiment was made as follows. A lamination technique was used to prepare a piece of paper pad so that it could be used as a filter for RNA in the same manner of the commercially available nucleic acid purification spin column. The chaotropic-salt-based buffers from QIAamp Viral RNA Mini Kit (QIAGEN) was used to improve RNA binding to the paper substrate. The polycarbonate container 3 ( FIG. 1B ) was attached to the laminated paper pad as a sample well to form the paper-based RNA amplification device. Instead of centrifugation force, sample filtration was powered by capillary forces generated in porous paper and the absorbent pad beneath the paper-based RNA amplification device. H1N1 flu virus was used to demonstrate RNA purification and amplification in the device 2 . The amplicons were analyzed using agarose gel electrophoresis and ethidium bromide staining.
- the FTA® card is a commercialized filter paper specifically treated to extract, bind, and preserve nucleic acids from blood, plant and animal tissue extracts and other sources according to the manufacturer.
- the chromatography paper is an untreated, high quality cellulose fiber paper.
- the GF/F glass microfiber filter is a paper specifically designed for nucleic acid purification. Paper-based devices made of FTA® card, glass microfiber and chromatography paper were tested with different concentrations of H1N1 virus lysis to compare the limit of detection (LOD). The results indicated that the device made of chromatography paper had the lowest LOD, detected spiked samples of 0.8 TCID 50 flu virus, while the device made of FTA® card and glass microfiber detected 5 TCID 50 .
- Untreated cellulose has been used as a nucleic acid isolation material since the 1960s, though its use is far less common than silica. This is possibly due to the complicated steps of assembling cellulose powder into a column often involved. Those manual steps make the cellulose powder less desirable compared to the ready-to-use silica column.
- the laminated paper-based RNA amplification device 2 is easy to make, of low cost, and does not require complicated manual steps during usage. The result discussed above suggests that the cellulose chromatography paper has a great potential as a RNA extraction substrate. As a result, all of the following experiments were performed using devices made from chromatography paper. It should be noted, however, that the inventive principles and concepts are not limited to using any particular type of extraction/amplification device for this purpose.
- a H1N1 flu virus spiked water of 140 ⁇ L was lysed with 560 ⁇ L buffer AVL and tested with the SPRA apparatus 1 to evaluate its performance in handling samples with the same volume range of those collected by the VIVAS 12 at 6 LPM for 15 minutes.
- the volume ratio of sample-lysis-ethanol was kept at 1:4:4 as instructed by the QIAamp Viral RNA mini Kit's manufacturer.
- RNA purification and amplification process each took roughly 25 minutes to complete, after which the result could be read using SYBR green dye and blue LED flashlight without lab instruments.
- 1 TCID 50 H1N1 flu virus per 140 ⁇ L sample was successfully detected in one hour using the SPRA apparatus 1 .
- the SYBR green-DNA-complex absorbs blue light and emits green light, resulting in a light-yellow color ( FIG. 5A ) when observed under the ambient light and a bright green fluorescence under blue LED ( FIG. 5B ).
- SYBR green was chosen for the experiment as it detects the DNA amplicons directly, while other colorimetric RT-LAMP methods such as the hydroxynaphthol blue, the leuco crystal violet, and the phenol red 39 detect the by-products of DNA amplification.
- the average collection volume of the integrated SPRA-VIVAS system for a 15-minute sampling using 10 mL PBS/BSA media in the BANG and 6 LPM air flow rate for the VIVAS was determined by weighing the SPRA collector 8 before and after collection to be 143 ⁇ 25 ⁇ L (mean ⁇ standard deviation).
- 560 ⁇ L lysis buffer was used in the SPRA collector 8 for the H1N1 flu virus aerosol detecting experiment.
- a virus concentration of 1 ⁇ 10 5 TCID 50 /mL H1N1 flu virus in PBS/BSA was used in the BANG and sampled in triplicates. According to the infectious H1N1 virus collection efficiency reported by the inventors in literature, the amount of collected H1N1 flu virus is above the sensitivity of the SPRA apparatus 1 .
- the SPRA apparatus 1 successfully detected the H1N1 flu virus aerosols generated in lab ( FIGS. 6A-6C ). No nonspecific amplification was observed in the negative control collection of PBS/BSA aerosols. Strong fluorescence signals were observed from all the triplicates of the H1N1 flu virus aerosol collections. Including the sampling time, one virus aerosol detection process only took around 65 minutes to complete, proving the SPRA apparatus 1 to be fast and effective in assessing airborne influenza virus transmission risks and/or in screening the presence of a certain type of airborne virus in the environment.
- the integrated SPRA-VIVAS platform detected lab-generated H1N1 flu virus aerosols in one hour.
- This system features a two-step concentration for the sporadic virus aerosols: (a) the concentration of liters of virus aerosols into a 150 ⁇ L aqueous sample, and (b) the filtration of lysed virus aerosol RNA onto the laminated paper pad.
- the two-step concentration provides the platform with the sensitivity required to detect virus aerosols using a rapid, specific RT-LAMP method.
- the laminated paper-based RNA amplification device 2 used as a filter was able to process a flexible amount of collected aerosol sample, thus allowing the sensitivity to be increased by increasing the collection time, i.e., the volume of aerosol collected by the VIVAS 12 , if necessary.
- the detection limit of the SPRA-VIVAS platform can be explored using virus aerosols of different concentrations and a portable optical sensor for quantitative detection.
- the collection of real-world virus aerosols can also be performed in places such as infirmaries and classrooms.
- the superior sensitivity and high portability of the SPRA apparatus 1 in RNA virus detection over the commercial FTA® card and WhatmanTM glass microfiber has been demonstrated herein.
- the SPRA apparatus 2 can also be used to detect virus from other types of aqueous samples.
- the apparatus and method for detecting non-airborne viruses will now be described with reference to a representative embodiment and an example application in which the virus being detected is the Zika virus.
- VLEAD valve-enabled lysis, paper-based RNA enrichment, and RNA amplification device (VLEAD) apparatus and method for sample-to-answer Zika virus detection are presented. It should be noted, however, that the VLEAD apparatus and method are suitable for providing sample-to-answer virus detection for viruses other than the Zika virus.
- the VLEAD apparatus comprises 3D-printed components for sample preparation and a laminated paper pad for RNA enrichment.
- the valving mechanism described above with reference to FIG. 1C is incorporated into the VLEAD apparatus design to enable RNA extraction to be conducted without the help of even basic lab equipment such as a pipette.
- untreated, cellulose chromatography paper is used as an RNA binding material to reduce the fabrication cost and potential inhibitory effect on RT-LAMP amplification.
- RT-LAMP amplification is performed using a commercially available, controllable, battery powered “smart” coffee mug (EmberTM Travel Mug) as a water bath to heat the device.
- a variety of portable electrical and chemical heaters have been developed for POC diagnostic devices using isothermal DNA amplification, but they are often not readily available to average users and thus require further fabrication and calibration.
- the EmberTM coffee mug is carried by many Starbucks® coffee shops in the U.S. and major online vendors such as Amazon and eBay, and its temperature can be accurately controlled using a smartphone software application program (App).
- App smartphone software application program
- a SYBR green dye and a relatively inexpensive blue LED flashlight are used to get an explicit fluorescence signal from the positive test.
- the duration Zika virus can be detected in blood, saliva, urine and semen ranges from days to months after symptom onset.
- the inventors have chosen urine and saliva to demonstrate that the sample collection processes performed using the VLEAD apparatus and method are simple and non-invasive.
- the inventors also used Zika virus spiked water to compare the sensitivity of the VLEAD apparatus with a commercial QIAamp Viral RNA mini Kit (QIAGEN). After validating the VLEAD apparatus and method using Zika virus spiked samples, the inventors successfully detected Zika virus in a clinical urine sample collected in 2016.
- FIGS. 7A-7D are perspective views of components comprising the VLEAD apparatus 20 in accordance with a representative embodiment.
- the VLEAD apparatus 20 comprises three parts, namely, a buffer unit 21 ( FIG. 7A ), a collector or mixing unit 22 ( FIG. 7B ) (referred to hereinafter as “the mixing unit 22 ”), and a detection unit 23 ( FIG. 7C ), which may be identical to paper-based RNA amplification device 2 shown in FIG. 1A .
- the mixing unit 22 is integrated with the detection unit 23 by inserting the bottom protrusion 28 ( FIG. 7B ) of the mixing unit 22 into the center hole 26 in the detection unit 23 with a piece of double-sided adhesive tape disposed between the two units being used to fix them together.
- the buffer unit 21 is slidably coupled with the mixing unit 22 via a sliding mechanism 27 .
- the sliding mechanism 27 comprises a pair of rails 27 a on the mixing unit 22 that engages a pair of grooves 27 b on the buffer unit 21 .
- the devices were printed from polylactic acid (PLA) with polyvinyl alcohol (PVA) as support material.
- the print layer height was set to 0.06 mm and the infill density was set to 100%.
- Both the buffer unit 21 and the mixing unit 22 can also be made by injection molding, machining, and other methods, as will be understood by those of skill in the art in view of the description provided herein.
- the detection unit 23 contained a polycarbonate container, a double-sided adhesive tape, and a laminated paper pad.
- a 3.5-mm-diameter circle of the WhatmanTM 1 chromatography paper (Fisher Scientific, Pittsburgh, Pa., USA) was made using a steel puncher.
- Two layers of thermoplastic films were shaped by cutting a section of 75 ⁇ m thick polyester thermal bonding lamination films (Lamination Plus, Kaysville, Utah, USA) using a Graphtec Craft Robo-S cutting plotter (Graphtec Corporation, Yokohama, Japan).
- the paper pad and the cover and bottom films were then aligned and passed through a heated laminator (GBC® Catena 65 Roll Laminator, GBC, Lake Zurich, Ill., USA), which was set at a rolling speed of “1” with the temperature at 220° F.
- a heated laminator GBC® Catena 65 Roll Laminator, GBC, Lake Zurich, Ill., USA
- the laminated paper pad was attached to a 3 mm thick, 2 cm-by-2 cm square polycarbonate container via a piece of 3M 9087 white bonding tape (R. S. Hughes, Sunnyvale, Calif.) to form the RNA detection unit.
- the container was shaped from a piece of clear polycarbonate sheet (McMaster-Carr, Elmhurst, Ill.) using a milling machine (Sherline Products, Vista, Calif.). A photo of the device is shown in FIGS. 8( a ) and ( b ) with a quarter as a comparison in size.
- Fluid control valves 31 ( FIG. 7D ), that are identical to the fluid control valve shown in FIG. 1D in accordance with this representative embodiment, are disposed in the buffer unit 21 for triggering the release of buffers from the buffer unit 21 into the reservoir 22 a of the mixing unit 22 .
- a 4-mm-diameter opening 29 was designed at the bottom of the funnel-shaped reservoirs 21 a - 21 d of the buffer unit 21 to house a stainless-steel bearing ball 24 .
- This opening 29 was designed in a way that the bearing ball 24 blocks the opening while protruding 1.5 mm from the bottom of the buffer reservoirs 21 a - 21 d .
- Two rectangular gaps 22 b are formed in a wall 22 c of the mixing unit 22 so that the bearing ball can pass through while the buffer unit 21 slides along the mixing unit 22 .
- the bearing ball 29 functions as a plug to keep the buffer from flowing out of the reservoirs 21 a - 21 d until the bearing ball 29 is pushed up by the post 25 of the mixing unit 22 when the mixing unit 22 is sliding along the buffer unit 21 .
- FIGS. 8A-8C are photographs of the apparatus shown in FIGS. 7A-7D and its components.
- a sealing system was employed using wax and cover film to seal the buffer unit 21 ( FIG. 8C ).
- a small amount of AkrowaxTM 130 (Akrochem, Akron, Ohio, USA) was placed at the bearing ball 24 to melt and re-solidify, so that it could form a breakable bond between the bearing ball 24 and the buffer unit 21 .
- the bottom of the buffer unit 21 was further protected by sliding it into a device holder 35 ( FIG. 8C ).
- a piece of polycarbonate film was taped to the top of the buffer unit 21 via double-sided adhesive to prevent buffer evaporation and spillage, and then the buffer unit 21 coupled to the device holder 35 ( FIG. 8C ) was ready for shipping and/or long-term storage.
- Vero E6 (CRL-1586; African green monkey kidney epithelial cells) were obtained from American Type Culture Collection (ATCC, Manassas, Va., USA) and cultured in Advanced Dulbecco's Modified Eagle's medium (aDMEM) with 10% low antibody, gamma-irradiated, heat inactivated fetal bovine serum (FBS), GlutaMAX, and Penicillin-Streptomycin-Neomycin (PSN) at 37° C. with 5% CO 2 .
- aDMEM Advanced Dulbecco's Modified Eagle's medium
- FBS gamma-irradiated, heat inactivated fetal bovine serum
- GlutaMAX gamma-irradiated fetal bovine serum
- PSN Penicillin-Streptomycin-Neomycin
- ZIKV Zika virus
- PRVABC59 Biodefense and Emerging Infections Research Resources Repository
- the strain was grown up for a lab stock by inoculating 475 ⁇ L media (aDMEM with 3% FBS, GlutaMAX, and PSN) with a ratio of 25 ⁇ L virus to a monolayer of Vero E6, and gently rocking once every 15 minutes at 37° C. with 5% CO 2 for 1 hour.
- a T25 (25 cm 2 growth surface) flask with Vero E6 cells at 60% confluency was used for observation of ZIKV-induced cytopathic effects (CPE).
- Plaque assays were performed to quantitate PRVABC59 and obtain viral titers, with newly confluent Vero E6 cells in a 6-well plate, to which 250 ⁇ L of virus dilutions of 10 2 , 10 3 , 10 4 , 10 5 , and 10 6 in aDMEM were added to each well. After inoculation, the 6-well plates were rocked every 15 minutes for two hours at 37° C. with 5% CO 2 .
- RNA extracted from Zika virus was used to conduct RT-LAMP.
- Each of 25 ⁇ L RT-LAMP system contains 2.5 ⁇ L of 10 ⁇ isothermal amplification buffer, 2.5 ⁇ L of 10 ⁇ primer mix, 8 U Bst 2.0 WarmStart® DNA Polymerase, 7.5 U WarmStart® RTx Reverse Transcriptase, a final concentration of 1.4 mM dNTPs and 6 mM MgSO 4 , and 1 ⁇ L RNA sample.
- the 25-4, volume was brought up by molecular-biology-grade water.
- ThermoFisher Scientific (MA, USA)
- other reagents in the RT-LAMP system were obtained from New England Biolabs (Ipswich, Mass., USA).
- the primer mix contains 1.6 ⁇ M F1P/B1P, 0.2 ⁇ M F3/B3, and 0.8 ⁇ M LF/LB, and the sequences of possible primers are listed below in Table 2.
- the primers were designed following the literature and obtained from Integrated DNA Technologies (Coralville, Iowa, USA). The inventors used the first set of primers in Table 2 though other sets of primers can be used, as will be understood by those of skill in the art in view of the description provided herein.
- the RT-LAMP system was incubated at 67° C. for 30 minutes in a Bio-Rad Mycycler® (Bio-Raid, CA, USA). The amplicons were confirmed with 2% agarose gel electrophoresis. Gel bands were imaged using a Gel DocTM EZ system (Bio-Rad).
- RT-LAMP assay For real-time detection of the RT-LAMP assay, 0.5 ⁇ L of 1:1000 diluted 10,000 ⁇ concentrate SYBR green I nucleic acid gel stain in DMSO and 0.5 ⁇ L ROX reference dye (ThermoFisher Scientific) were added to the 25 ⁇ L RT-LAMP reaction buffer. The fluorescence signal was read through the QuantStudio 3 real-time PCR system (ThermoFisher Scientific).
- Zika samples were made by spiking 1 ⁇ L Zika virus at various concentrations to 140 ⁇ L of media. Water, human urine, and human saliva (Innovative Research, Novi, Mich.) were used to test the VLEAD's sensitivity. For safety concern, the Zika virus samples were mixed with the AVL lysis buffer (QIAGEN) at the ratio of 1:4 in a biosafety facility before bringing out to perform the test.
- AVL lysis buffer QIAGEN
- FIGS. 9A-9F depict the method for using the apparatus shown in FIGS. 7A-7D to perform testing.
- Two washing buffers (AW1 and AW2 buffer in QIAamp Viral RNA mini Kit) of 200 ⁇ L each, a binding buffer (200 proof ethanol) of 560 ⁇ L and a lysis buffer of 560 ⁇ L (buffer AVL, QIAGEN) were pre-loaded into their designated reservoirs 21 a - 21 d ( FIG. 7A ) in the VLEAD buffer unit 21 .
- the Zika virus sample was first loaded into the lysis buffer reservoir 21 d ( FIG. 9A ) and discharged into the mixing unit 22 through sliding the buffer unit 21 to actuate the bearing ball valve ( FIG.
- the detection unit 23 was further placed on a piece of blotting paper to filter the lysate through the laminated paper pad in the detection unit 23 ( FIG. 9C ).
- the paper pad functioned as a SPE material to enrich the Zika virus RNA from the lysate.
- the time cost by the blotting process depended on the type and volume of Zika sample used. The spiked samples tested by the inventors took no longer than 20 minutes to filter through the paper pad completely.
- the buffer unit 21 was further slid twice to discharge the two washing buffers 21 b and 21 a to purify the captured RNA ( FIG. 9D ).
- RNA enrichment After RNA enrichment, the buffer unit 21 and mixing unit 22 were separated from the detection unit 23 . To detect the RNA captured, a piece of adhesive tape (Fellows®) was attached to the bottom to prevent amplification buffer leakage. A RT-LAMP amplification buffer of 25 ⁇ L was loaded to the detection unit 23 , which was then sealed with another piece of adhesive tape on the top ( FIG. 9E ). The sealed detection unit 23 was incubated either in a travel mug ( FIG. 13D ) or in a water bath at 67° C. for 25 minutes in an Isotemp 105 water bath (ThermoFisher Scientific) for DNA amplification.
- a piece of adhesive tape (Fellows®) was attached to the bottom to prevent amplification buffer leakage.
- a RT-LAMP amplification buffer of 25 ⁇ L was loaded to the detection unit 23 , which was then sealed with another piece of adhesive tape on the top ( FIG. 9E ).
- the sealed detection unit 23 was incubated either
- the inventors chose to use a commercially available, battery powered coffee mug ( FIG. 13D , EmberTM Travel Mug, Ember Technologies, Inc., Westlake Village, Calif.) which can heat water up to 62.5° C. and maintain the temperature for two hours once the rechargeable battery has been fully charged.
- the EmberTM mug also features adjustable temperature and real-time temperature display, which makes it suitable for incubating isothermal PCR such as the nucleic acid sequence-based amplification (NASBA) and LAMP.
- NASBA nucleic acid sequence-based amplification
- the inventors purified Zika spiked water samples using the VLEAD apparatus 20 , and submerged the VLEAD detection unit 23 directly into the water in the coffee mug after the maximum 62.5° C. had been reached. The detection unit 23 was incubated for 25 minutes before being taken out to check the amplification result.
- FIG. 10A is a plot depicting curves 101 - 103 representing normalized fluorescent signals of 5, 50, and 500 PFU Zika virus genome equivalents amplification by RT-LAMP, respectively, showing that all samples' amplification signals reached the plateau in 15 min.
- Curve 104 represents NTC.
- FIG. 10B depicts a standard curve (log PFU per reaction vs. threshold time) generated with three replicates of each of the serial diluted Zika virus RNA samples.
- the QIAamp Viral RNA Mini Kit (QIAGEN) was used as a bench top standard to purify RNA from Zika virus spiked water.
- Fluorescence readings were taken from RT-LAMP containing 5, 50 and 500 PFU RNA equivalents using the QuantStudio 3 real-time PCR system ( FIG. 10 ). All the positive wells were amplified within 15 minutes, and no non-specific amplification was observed during the 30-minute incubation period.
- FIGS. 11A-11C are photographs of the detection unit 23 corresponding to the results under the ambient light ( FIG. 11A ) and blue LED flashlight ( FIG. 11B ).
- FIG. 11C shows a gel electrophoresis image of the amplicons from each device. From left lane to right: 100 bp DNA marker, 1, 0.5, 0.1 PFU and NTC. The results shown in FIGS.
- 11A-11C indicate that the VLEAD apparatus 20 achieved comparable performance with the commercial QIAGEN kit, with 3/3 detected from 0.1 PFU Zika virus spiked water samples using the VLEAD apparatus 20 and method versus 1 ⁇ 3 detected using the QIAGEN kit.
- the impurities in those samples only affected the sensitivity slightly, with 1 ⁇ 3 0.1 PFU Zika spiked urine detected and 5 ⁇ 6 0.1 PFU Zika spiked saliva detected.
- the VLEAD apparatus 20 and method integrate all of the steps required for virus nucleic acid amplification test, from virus lysis, nucleic acid enrichment, purification, to amplification. As a result, there is no need to transfer RNA samples between different tubes, which greatly reduces the chance of sample contamination.
- RNA enrichment process of the VLEAD apparatus 20 is driven by the capillary forces generated by the laminated paper pad and blotting paper, thus eliminating the need to use lab equipment such as, for example, a centrifuge.
- lab equipment such as, for example, a centrifuge.
- the RNA purified on the column needs to be eluted before downstream application.
- the elution step leads to sample dilution and comes with a “dead volume” absorbed on the column.
- all of the RNA purified on the paper pad could be used for nucleic acid amplification testing such as reverse transcription polymerase chain reactions (RT-PCR).
- isothermal DNA amplification techniques other than LAMP, including strand displacement amplification (SDA) and helicase-dependent amplification (HDA), can also be used, as will be understood by those of skill in the art in view of the description provided herein.
- SDA strand displacement amplification
- HDA helicase-dependent amplification
- the VLEAD method employed SYBR green to visualize the DNA amplicons through the green fluorescence excited by a handheld blue LED flashlight ( FIG. 9F ) from the DNA-dye-complex. Due to the high concentration of SYBR green required by naked-eye observation inhibiting the RT-LAMP enzymes, the dye was not included within the RT-LAMP buffer before the incubation step.
- Other known colorimetric approaches such as, for example, those that use hydroxynaphthol blue, leuco crystal violet or phenol red, detect the by-products of RT-LAMP. These approaches often have less differences between the positive and negative results and therefore wasn't incorporated into the VLEAD method of the representative embodiment.
- the inventors Using the VLEAD apparatus 20 , the inventors also tested a de-identified clinical urine sample collected from one Zika patient in Venezuela in 2016. The presence of Zika virus had been confirmed using plaque assay. The sample had been stored in a ⁇ 80° C. freezer for two years before being tested using the VLEAD apparatus 20 and method. During the testing, the inventors observed slow filtration during the RNA enrichment step. As a result, the inventors reduced the sample volume to 100 ⁇ L to keep the blotting time around 20 minutes. A positive control of 10 PFU Zika virus spiked water and a negative control of DI water were made to validate the assay.
- FIGS. 12A-12C are photographs of the detection unit 23 showing the test results.
- FIG. 12A is a photograph of the detection unit 23 under ambient light and
- FIG. 12B is a photograph of the detection unit 23 under a blue LED flashlight.
- FIG. 12C is a gel electrophoresis image of the amplicons from each device; from left lane to right: 100 bp DNA marker, positive control (P), clinical sample (S), and NTC. The presence of Zika virus was detected but the signal was somewhat weak, probably due to RNA degradation during the sample storage. The inventors repeated the experiment using two more aliquots from the same patient and were able to detect 2 ⁇ 3 of all the three aliquots.
- the slow filtration observed in this testing could be caused by an increased amount of cell debris in the patient's urine related to disease progression or precipitations formed during the two-year storage. This issue is expected to be significantly less in fresh samples. Further it could potentially be solved by diluting the sample with water or digesting the sample with Proteinase K before sample loading.
- FIGS. 13A-13D Using the EmberTM travel mug as an incubator for RT-LAMP, the inventors successfully detected the 100, 10, and 1 PFU Zika RNA equivalents purified in the VLEAD apparatus 20 in 25 minutes ( FIGS. 13A-13D ).
- FIG. 13A is a photograph of the detection unit 23 under ambient light and
- FIG. 13B is a photograph of the detection unit 23 under a blue LED flashlight.
- FIG. 13C is a gel electrophoresis image of the amplicons from each device; from left lane to right: 100 bp DNA marker, positive control (P), clinical sample (S), and NTC.
- the cup shown in FIG. 13D has a volume capacity of 12 oz. which is more than enough volume to submerge the detection unit 23 .
- the cup was filled close to the “MAX” line to reduce the temperature fluctuation upon adding the detection units 23 during the test. Even though the primer set that was used was optimized at 67° C., which is above the maximum temperature achievable by the EmberTM coffee mug without further customization, the LAMP method is sufficiently robust at a range of temperatures from 57° C. to 67° C.
- FIG. 14 is a plot of a temperature calibration curve 140 for calibrating the EmberTM mug shown in FIG. 13D .
- Each data point on the curve 140 was measured three times with 5 min in between.
- the temperature of the EmberTM mug was first calibrated using a thermocouple which was inserted through a small opening in the lid designed for pressure release.
- the water temperature inside the mug was set and measured at 52.5° C., 55.0° C., 57.5° C., 60.0° C., and 62.5° C. Three measurements were taken for each temperature, with 1, 6, and 11 minutes after the temperature displayed by the EmberTM mug App had reached the set temperature.
- FIGS. 15A and 15B are photographs showing detection results under ambient light and blue LED flashlight, respectively, obtained by the apparatus 20 shown in FIGS. 7C and 9A-9F for detection of 14 ⁇ l of ZIKV-spiked urine samples using the detection unit 23 .
- Devices 1 - 4 shown in FIGS. 15A and 15B contain 10, 1, 0.5 and 0.1 PFU ZIKV, respectively.
- Device 5 functions as the negative control.
- This detection limit in terms of the absolute amount of virus, 0.5 PFU ZIKV per device, is the same as using 140 ⁇ l of ZIKV-spiked urine samples with state-of-the-art system discussed above in Table 3.
- the detection limit in terms of the virus concentration or “PFU per volume” is lowered by 10 times when a large volume of samples is used. The results also suggest that essentially all RNA molecules are captured by the paper pad of the detection unit.
- FIG. 16 is a flow diagram representing the method in accordance with a representative embodiment.
- Block 161 represents a step of collecting and holding at least a first liquid sample.
- Block 162 represents a step of allowing the first liquid sample to interact with at least a second liquid to cause nucleic acids to be released from the first liquid sample.
- Block 163 represents a step of concentrating nucleic acids that have been released from the first liquid sample.
- Block 164 represents a step of washing the concentrated nucleic acids using at least third and fourth liquids.
- Block 165 represents a step of amplifying the concentrated nucleic acids at an isothermal temperature to produce amplified products.
- Block 166 represents a step of detecting the amplified products.
- the VLEAD apparatus 20 and method achieve comparable sensitivity with a commercial SPE RNA extraction kit.
- Untreated cellulose has been used as a nucleic acid extraction material since the 1960s.
- its use in nucleic acid SPE is far less common nowadays compared to other materials such as silica 2 and chitosan.
- the mechanism of RNA absorption by cellulose fibers is also poorly understood due to lack of study.
- the VLEAD detection unit 23 made of laminated cellulose paper is uncomplicated, easy-to-use, of low cost and very sensitive in detecting RNA.
- the above results indicate that cellulose chromatography paper is a good alternative in developing platforms for nucleic acid extraction.
- the VLEAD apparatus 20 was tested with human saliva and urine samples spiked with Zika virus.
- the disposable, 3D printed components allow the laminated paper pad to process a much larger sample volume ( ⁇ 100 ⁇ L) compared to traditional microfluidic paper-based analytical devices (less than 10 ⁇ L) and thus increase the sensitivity of the VLEAD apparatus 20 .
- the VLEAD apparatus 20 was able to stably detect 0.5 PFU from Zika virus spiked urine and salvia and 0.1 PFU from Zika virus spiked water.
- the VLEAD apparatus 20 and method can be used to perform an innovative and highly sensitive POC test for Zika virus and other viruses using paper and 3D printed materials.
- the VLEAD platform can also be used in detecting other microorganisms with different primers for RT-LAMP or other DNA amplification techniques.
- the apparatuses 1 and 20 and corresponding methods have been demonstrated for two RNA viruses, they can be easily expanded into both DNA and RNA viruses. For DNA viruses, it will be even simpler since it does not need the reverse transcription step that transcripts RNA to DNA. Those of skill in the art will understand how the apparatuses 1 and 20 can be adapted for detecting bacteria, fungi, and other pathogens, which can be lysed to produce nucleic acids, followed by amplification and detection.
- Each 25-4, RT-LAMP mix contains 2.5 ⁇ L of 10 ⁇ isothermal amplification buffer, 8 U Bst 2.0 WarmStart® DNA polymerase, 7.5 U WarmStart® RTx reverse transcriptase, 2.5 ⁇ L of 10 ⁇ concentrated primer mix, and a final concentration of 1.4 mM dNTPs and 6 mM MgSO 4 .
- the 25- ⁇ L volume was filled up by nuclease-free water (not DEPC treated).
- ThermoFisher Scientific (MA, USA)
- the other reagents in the RT-LAMP mix were obtained from New England Biolabs (Ipswich, Mass., USA).
- the 10 ⁇ primer mix for SARS-CoV-2 contains 16 ⁇ M FIP/BIP, 2 ⁇ M F3/B3, and 8 ⁇ M LF/LB (Table 4 below).
- the primers were obtained from Integrated DNA Technologies (Coralville, Iowa, USA), and were chosen by following the literature.
- UDG RT-LAMP reaction mix 0.5 units of Antarctic Thermolabile uracil-DNA glycosylase (UDG), and 0.7 mM of dUTP solution (New England Biolabs) were added to the RT-LAMP mix previously described, reducing the amount of nuclease-free water needed for the reaction.
- UDG Antarctic Thermolabile uracil-DNA glycosylase
- dUTP solution New England Biolabs
- the genome copy equivalents per microliter (GCEs/ ⁇ L) of the extracted RNA was calculated using a standard curve on a rRT-PCR assay, which was determined to be 1 ⁇ 10 6 GCEs/ ⁇ L. 10-fold serial dilutions were made using RNA storage solution (Invitrogen), and 1 ⁇ L of purified RNA of the different concentrations was added into 25-4, UDG RT-LAMP reactions, along with a non-template control.
- the RT-LAMP assay for SARS-CoV-2 detection showed high sensitivity with a low limit of detection of less than 10 GCEs.
- FIGS. 17A-17D are images depicting sensitivity tests for the SARS-CoV-2 RT-LAMP assay, incubating at 62.5° C. for 25 min. The tests demonstrated the ability to detect as low as a 10 6 dilution of the purified SARS-CoV-2 RNA that was about 10 6 GCE per microliter. Thus, the method and apparatus were able to detect less than 10 GCEs. From left to right, the units are in the following order: 10 4 dilution, 10 5 dilution, 10 6 dilution, and a no template control. All of the concentrations were amplified after 25 minutes.
- FIG. 17A is photo taken under room lights
- FIG. 17B is a photo taken under room lights and blue LED
- FIG. 17C is a photo taken under blue LED with the room lights off
- FIG. 17D shows confirmation of results by gel electrophoresis.
- an apparatus for preparing a sample for use in detecting microorganisms comprises a collector unit, a buffer unit, a mechanical coupling mechanism and a valve mechanism.
- the collector unit has at least a first reservoir for holding at least a first liquid sample.
- the buffer unit includes at least second, third and fourth reservoirs for holding at least second, third and fourth liquids, respectively.
- the mechanical coupling mechanism couples the collector unit and the buffer unit together in a manner that allows a user to create relative movement between the collector unit and the buffer unit by exerting a force on at least one of the buffer unit and the collector unit.
- the valve mechanism causes the second, third and fourth liquids to be released from the second, third and fourth reservoirs, respectively, into the first reservoir, in turn, when the user creates relative movement between the collector unit and the buffer unit to cause the second, third and fourth reservoirs to come into temporary alignment with the first reservoir for respective time periods.
- the apparatus further comprises a detection unit removably coupled to the collector unit for detecting microorganisms.
- the detection unit receives liquid from the first reservoir and can be removed from the collector unit and analyzed to determine whether the liquid received by the detection unit contains a particular microorganism.
- the collector unit is rotatably coupled to the buffer unit by the mechanical coupling mechanism such that the relative movement is created by the user exerting the force on the buffer unit to cause the buffer unit to rotate relative to the collector unit, thereby causing the second, third and fourth reservoirs to come into temporary alignment with the first reservoir for the respective time periods during which the second, third and fourth liquids are released, in turn, into the first reservoir.
- the valve mechanism comprises a post, a first valve, a first ball, a second valve, a second ball, a third valve and a third ball.
- the post has a proximal end connected to a surface of the collector unit and a distal end opposite the proximal end.
- a first valve opening is disposed in a bottom of the second reservoir.
- the first ball is movably positioned in the first valve opening when the first valve opening is in a closed state.
- the post comes into contact with the first ball to move the first ball away from the first valve opening to thereby place the first valve opening in an opened state.
- a second valve opening is disposed in a bottom of the third reservoir.
- the second ball is movably positioned in the second valve opening when the second valve opening is in a closed state.
- the post comes into contact with the second ball to move the second ball away from the second valve opening to thereby place the second valve opening in an opened state.
- a third valve opening is disposed in a bottom of the fourth reservoir.
- the third ball is movably positioned in the third valve opening when the third valve opening is in a closed state.
- the post comes into contact with the third ball to move the third ball away from the third valve opening to thereby place the third valve opening in an opened state.
- the detection unit is a paper-based detection unit removably coupled to a bottom side of the collector unit.
- the first reservoir of the collector unit has an opening therein through which liquid held in the first reservoir passes and is received by the paper-based detection unit.
- the paper-based detection unit is a laminated paper-based RNA amplification component.
- the particular microorganism is a virus.
- the virus is selected from the group comprising influenza virus, Zika virus, Dengue virus, Chikungunya virus, Ebola virus, hepatitis A virus, hepatitis B virus, hepatitis C virus, human immunodeficiency viruses (HIV) and Mayaro virus.
- the particular microorganism is a bacterium.
- the bacterium is selected from the group comprising Escherichia coli ( E. coli ), enterococci, Salmonellae, Streptococcus pneumoniae, Staphylococcus aureus and Pseudomonas aeruginosa.
- the buffer unit further includes at least fifth reservoir for holding at least a fifth liquid.
- the valve mechanism causes the second, third, fourth and fifth liquids to be released from the second, third, fourth and fifth reservoirs, respectively, into the first reservoir, in turn, when the user creates relative movement between the collector unit and the buffer unit to cause the second, third, fourth and fifth reservoirs to come into temporary alignment with the first reservoir for respective time periods.
- the valve mechanism further comprises a fourth valve opening disposed in a bottom of the fifth reservoir and a fourth ball movably positioned in the fourth valve opening when the fourth valve opening is in a closed state.
- the fifth reservoir is in temporary alignment with the first reservoir, the post comes into contact with the fourth ball to move the fourth ball away from the fourth valve opening to thereby place the fourth valve opening in an opened state.
- the collector unit and the buffer unit are slidably coupled to one another by the mechanical coupling mechanism such that when the user exerts the force on at least one of the buffer unit and the collector unit, one of the buffer unit and the collector unit slides relative to the other, thereby causing the second, third, fourth and fifth reservoirs to come into temporary alignment with the first reservoir for the respective time periods during which the second, third, fourth and fifth liquids are released, in turn, into the first reservoir.
- the detection unit is a paper-based detection unit removably coupled to a bottom side of the collector unit. The first reservoir of the collector unit has an opening therein through which liquid held in the first reservoir passes and is received by the paper-based detection unit.
- the paper-based detection unit is a laminated paper-based RNA amplification component.
- a method for preparing a sample to be used for detecting microorganisms.
- the method comprises placing a first liquid sample in at least a first reservoir of a collector unit of a microorganism detecting apparatus, placing at least second, third and fourth liquids in at least second, third and fourth reservoirs, respectively, of a buffer unit of the microorganism detecting apparatus, wherein the collector unit and the buffer unit are coupled together by a mechanical coupling mechanism in a manner that allows a user to create relative movement between the collector unit and the buffer unit by exerting a manual force on at least one of the buffer unit and the collector unit; and exerting the manual force on at least one of the buffer unit and the collector unit to create relative movement between the collector unit and the buffer unit to cause the second, third and fourth reservoirs to come into temporary alignment with the first reservoir for respective time periods, wherein a valve mechanism of the microorganism detecting apparatus causes the second, third and fourth liquids to be released from the second, third and fourth reservoirs, respectively, into the
- the method further comprises, with a detection unit removably coupled to the collector unit, receiving liquid from the first reservoir, and removing the detection unit from the collector unit and analyzing the detection unit to determine whether the liquid received by the detection unit contains a particular microorganism.
- a method for preparing a sample for use in detecting microorganisms comprising, collecting and holding at least a first liquid sample, allowing the first liquid sample to interact with at least a second liquid to cause nucleic acids to be released from the first liquid sample, concentrating nucleic acids that have been released from the first liquid sample, washing the concentrated nucleic acids using at least third and fourth liquids, amplifying the concentrated nucleic acids at an isothermal temperature to produce amplified products, and detecting the amplified products.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Sustainable Development (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Clinical Laboratory Science (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Computer Hardware Design (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Abstract
Description
- This application is a continuation-in-part bypass application that claims priority to, and the benefit of the filing date of, PCT international application No. PCT/US2019/044490, filed on Jul. 31, 2019 and entitled “APPARATUS AND METHOD FOR PERFORMING MICROORGANISM DETECTION,” which claims priority to, and the benefit of the filing date of, U.S. Provisional Application having Ser. No. 62/712,571, filed on Jul. 31, 2018 and entitled “APPARATUS AND METHOD FOR PERFORMING MICROORGANISM DETECTION,” both of which are incorporated by reference herein in their entireties.
- This invention was made with government support under Grant No. 2030844 awarded by the National Science Foundation, and Grant No. 1353423 awarded by the National Science Foundation. The government has certain rights in the invention.
- The genetic components described herein are referred to by sequence identifier numbers (SEQ ID NO). The SEQ ID NOs correspond numerically to the sequence identifiers <400>1, <400>2, etc. The sequence listing in written computer readable format (CRF) is submitted Apr. 19, 2021, as a text file named “222107-1315 Sequence Listing ST25.txt” created on Apr. 19, 2021, and has a size of 15,114 bytes.
- This invention was created in part by funding received from Grant No. 7ZK22 of the Zika Research Grant Initiative Project awarded by the Florida Department of Health, Biomedical Research Program, for The State of Florida.
- This present disclosure relates to methods and apparatuses for detecting microorganisms.
- The recent global outbreaks of Zika virus disease and its association with neurological complications represent a long-term public health challenge. Zika virus is a mosquito-borne flavivirus (family Flaviviridae) that caused epidemics in Brazil in 2015 and spread quickly into the United States. The Zika virus disease became a nationally notifiable condition in 2016. Zika virus was first isolated from a non-human primate in 1947 in Africa. Zika virus infections in humans were sporadic before the first outbreak in 2007 and thought to be mainly asymptomatic, some causing dengue-like symptoms such as fever, headache, rash, arthralgia, myalgia and conjunctivitis. Since the French Polynesian outbreak in 2013, however, Zika virus disease has been associated with severe neurological complications, including Guillain-Barré syndrome (GBS) in adults and microcephaly in neonates.
- The modern international travel and dense population in cities greatly increase the ability of vector-borne diseases such as Zika to cause global epidemics. Moreover, developing countries where infectious diseases affect most people often lack well-equipped laboratories to conduct molecular diagnosis for viruses. As a result, it is vital to develop fast, reliable, portable and affordable diagnostic tools to monitor the emergence and the spread of Zika virus disease.
- The U.S. Centers for Disease Control and Prevention (CDC) recommend Zika virus RNA nucleic acid testing (NAT) and Zika virus and/or dengue virus IgM testing for symptomatic patients with possible Zika exposure. In countries with limited laboratory resources to preform molecular diagnosis, serological testing by IgM and IgG enzyme-linked immunosorbent assay (ELISA) or lateral flow assay (LFA) is often performed for the rapid diagnosis of similar flavivirus infections. However, due to the high level of structural similarity between the envelop protein of Zika virus and that of other flaviviruses, poor-specificity and cross-reactivity have been observed for antibodies elicited by Zika virus infection. Moreover, the sensitivity of rapid immunosorbent assay such as LFA is largely affected by the affinity of the specific antibody used by the test. Therefore, NAT such as reverse transcription polymerase chain reaction (RT-PCR) or reverse transcription loop-mediated isothermal amplification (RT-LAMP) is highly recommended when detecting Zika virus infection, especially for developing a point-of-care (POC) test for resource-limited regions. For DNA viruses, NAT can be PCR or LAMP. For other microorganisms such as Escherichia coli (E. coli) bacteria, NAT is PCR or LAMP. LAMP or RT-LAMP can also be replaced with other isothermal application methods including rolling circle amplification (RCA), helicase-dependent amplification (HDA), recombinase polymerase amplification (RPA), nucleic acid sequence-based amplification (NASBA), and others.
- RT-LAMP has been extensively used as a NAT for POC RNA virus detection system due to its robustness, high sensitivity and specificity, short incubation time, simplified thermal management and instrument-free product detection. Since the outbreak of Zika virus in 2013, a lot of RT-LAMP tests have been developed to specifically detect Zika virus RNA, some of which even have the ability to differentiate between Asian and African Zika linage.
- Even though the robustness of RT-LAMP allows extraction-free virus sample to be used for amplification in some circumstances, the small sample volume and the dilution steps involved decrease the sensitivity of the test. Traditional RNA extraction methods such as the organic extraction method and the solid phase extraction (SPE) method are often time-consuming and labor-intensive. The requirement for centrifugation equipment, various kinds of reagents and a controlled environment often makes it unrealistic for most circumstances outside of a lab. As a result, many microfluidic NAT devices have been developed for POC testing employing the SPE technique, incorporating elements such as silicon micropillars, silica monolith, SiO2 coating, packed silica beads and paramagnetic silica particles in microchannels. These devices, however, are expensive to make and often require lab instruments (e.g. syringe pump) to operate.
- Airborne infectious reagents, such as influenza viruses, coronaviruses, rhinoviruses and adenoviruses, can be transmitted through three primary routes: (a) inhalation of pathogen-containing aerosols, (b) droplet infection, and (c) contact transmission. Understanding the aerosol transmission mode is of great importance, as the risk of respiratory disease transmission through this route is exceptionally high in population-dense areas, such as schools, hospitals, airports and industrial animal farms. However, the relative importance of the aerosol transmission route among the three is controversial, due to the limitations in the sampling and detection methods available for small-sized virus aerosols. Moreover, traditional methods used to detect the collected virus aerosols, for example, viral culture and polymerase chain reactions (PCR), are time-consuming and labor-intensive. The requirements of well-equipped lab and highly-trained personnel often make it unrealistic in resource-limited settings.
- Compared to the great progress made to detect infecting agents present in other types of samples, such as aqueous samples, airborne pathogen detection is still a challenge and especially lacking in automated platforms with realistic and efficient sampling procedures. Due to the low pathogen content in aerosols, a huge volume of aerosols needs to be concentrated into a sub-milliliter-sized liquid typically used by biosensors to be detectable. The assignee of the present application has developed a Viable Virus Aerosol Sampler (VIVAS) as an efficient collector for the lab-generated, sub-micron-sized virus aerosols. The VIVAS is a laminar-flow, water-based condensational growth system capable of collecting aerosolized particles from 8 nm to 10 μm. The VIVAS has been successfully used to collect a variety of viable human respiratory viruses in a student infirmary of the University of Florida during a late-onset 2016 influenza virus outbreak as well as coronavirus disease 2019 (COVID-19). The high collection efficiency with the proven ability to collect real-world virus aerosols makes the VIVAS highly suitable for becoming a part of sample-to-answer virus aerosol detector.
- An ideal sample-to-answer virus aerosol detection system includes an efficient aerosols collector and a rapid, sensitive detector for the collected virus. Moreover, these two components should be integrated in a way to operate without manual steps or with the minimum amount of manual interventions. Rapid enzyme immunoassay-based POC testing for human respiratory diseases such as the QuickVue Influenza A+B Test has been available in hospitals for serval years. However, the enzyme immunoassay-based POC testing has lower sensitivities compared to NAT.
- Accordingly, a need exists for an improved method and apparatus for performing virus detection that can be operated with very little manual intervention, with high sensitivity, without the need for lab equipment, and that is suitable for POC testing in resource-limited regions.
- Many aspects of the invention can be better understood with reference to the following drawings. The components in the drawings are not necessarily to scale, emphasis instead being placed upon clearly illustrating the principles of the present invention. Moreover, in the drawings, like reference numerals designate corresponding parts throughout the several views.
-
FIGS. 1A-1E illustrates various aspects of the apparatus for detecting microorganisms in accordance with a representative embodiment. -
FIGS. 2A-2F illustrate the method for detecting microorganisms using the apparatus shown inFIGS. 1A-1E . -
FIGS. 3A-3E show photographs of the apparatus shown inFIGS. 1A-1E and the VIVAS that is used to collect the sample. -
FIG. 4A is a graph showing curves representing normalized fluorescent signals of 10, 100, and 1000 TCID50 H1N1 flu virus genome equivalents as a function of RT-LAMP time; the curves indicate that all samples' amplification signals reached the plateau in 20 minutes. -
FIG. 4B is a standard curve (log TCID50 per reaction vs. threshold time) generated with three replicates of each serial diluted H1N1 flu virus RNA samples. -
FIGS. 5A-5C are photographs showing how 1 TCID50 H1N1 flu virus per 140 sample was successfully detected in one hour using the apparatus shown inFIGS. 1A-1E . -
FIGS. 6A-6C are photographs showing how the apparatus shown inFIGS. 1A-1E was used to successfully detect the H1N1 flu virus aerosols generated in a lab. -
FIGS. 7A-7D are perspective views of the apparatus and components thereof in accordance with another representative embodiment. -
FIGS. 8A-8C are photographs of the apparatus shown inFIGS. 7A-7D . -
FIGS. 9A-9F illustrate the method for detecting microorganisms using the apparatus shown inFIGS. 7A-7D . -
FIG. 10A depicts curves representing normalized fluorescent signals of 5, 50, and 500 PFU Zika virus genome equivalents amplification by RT-LAMP showing that all samples' amplification signals reached the plateau in 20 min. -
FIG. 10B depicts a standard curve (log PFU per reaction vs. threshold time) generated with 3 replicates of each serial diluted Zika virus RNA samples. -
FIG. 11A is a photograph of the detection unit of the apparatus shown inFIGS. 7A-7D corresponding to the results under ambient light. -
FIG. 11B is a photograph of the detection unit of the apparatus shown inFIGS. 7A-7D corresponding to the results under light from a blue LED flashlight. -
FIG. 11C is a gel electrophoresis image of the amplicons from each device; from left lane to right: 100 by DNA marker, 1, 0.5, 0.1 PFU and NTC. -
FIGS. 12A and 12B are photographs of the detection unit of the apparatus shown inFIGS. 7A-7D under ambient light and light from a blue LED flashlight, respectively; P is the positive control S is a clinical sample, and NTC is no-template control. -
FIG. 12C is a gel electrophoresis image of the amplicons from each detection unit. -
FIG. 13A is a photograph showing Zika virus detection using the detection unit of the apparatus shown inFIGS. 7A-7D incubated in the Ember™ travel mug and analyzed under ambient light. -
FIG. 13B is a photograph showing Zika virus detection using the detection unit of the apparatus shown inFIGS. 7A-7D incubated in the Ember™ travel mug and analyzed under light from a blue LED flashlight. -
FIG. 13C is a gel electrophoresis image of the amplicons from each detection unit; from left lane to right: 100 bp DNA marker, 100, 10, 1 PFU and NTC. -
FIG. 13D is a photograph showing detection units submerged in water in an Ember™ travel mug. -
FIG. 14 is a plot of atemperature calibration curve 140 for calibrating the Ember™ mug shown inFIG. 13D . -
FIGS. 15A and 15B are photographs showing detection results under ambient light and blue LED flashlight, respectively, obtained by theapparatus 20 shown inFIGS. 7C and 9A-9F for detection of 14 μl of ZIKV-spiked urine samples. -
FIG. 16 is a flow diagram representing the method in accordance with a representative embodiment for preparing a sample for use in detecting microorganisms. -
FIGS. 17A-17D are images depicting sensitivity tests for the SARS-CoV-2 RT-LAMP assay, incubating at 62.5° C. for 25 min for results obtained using the method and apparatus described with reference toFIGS. 7A-7C . - The present disclosure discloses an apparatus and a method for performing microorganism detection. The apparatus is capable of detecting microorganisms (e.g., viruses) with high sensitivity, is well suited for POC testing in resource-limited regions and is capable of being operated with very little manual intervention and without the need for lab equipment. A collector unit of the apparatus comprises at least a first reservoir for holding at least a first liquid sample. A buffer unit of the apparatus includes at least second, third and fourth reservoirs for holding at least second, third and fourth liquids, respectively. A mechanical coupling mechanism of the apparatus couples the collector unit and the buffer unit together in a manner that allows a user to create relative movement between the collector unit and the buffer unit by exerting a force on at least one of the buffer unit and the collector unit. A valve mechanism of the apparatus causes the second, third and fourth liquids to be released from the second, third and fourth reservoirs, respectively, into the first reservoir, in turn, when the user creates relative movement between the collector unit and the buffer unit to cause the second, third and fourth reservoirs to come into temporary alignment with the first reservoir for respective time periods. A detection unit of the apparatus that is removably coupled to the collector unit receives liquid from the first reservoir. The detection unit can be removed from the collector unit and analyzed to determine whether the liquid received by the detection unit contains a particular microorganism.
- In the following detailed description, for purposes of explanation and not limitation, exemplary, or representative, embodiments disclosing specific details are set forth in order to provide a thorough understanding of the inventive principles and concepts. However, it will be apparent to one of ordinary skill in the art having the benefit of the present disclosure that other embodiments according to the present teachings that are not explicitly described or shown herein are within the scope of the appended claims. Moreover, descriptions of well-known apparatuses and methods may be omitted so as not to obscure the description of the exemplary embodiments. Such methods and apparatuses are clearly within the scope of the present teachings, as will be understood by those of skill in the art. It should also be understood that the word “example,” as used herein, is intended to be non-exclusionary and non-limiting in nature.
- The terminology used herein is for purposes of describing particular embodiments only, and is not intended to be limiting. The defined terms are in addition to the technical, scientific, or ordinary meanings of the defined terms as commonly understood and accepted in the relevant context.
- The terms “a,” “an” and “the” include both singular and plural referents, unless the context clearly dictates otherwise. Thus, for example, “a device” includes one device and plural devices. The terms “substantial” or “substantially” mean to within acceptable limits or degrees acceptable to those of skill in the art. For example, the term “substantially parallel to” means that a structure or device may not be made perfectly parallel to some other structure or device due to tolerances or imperfections in the process by which the structures or devices are made. The term “approximately” means to within an acceptable limit or amount to one of ordinary skill in the art. Relative terms, such as “over,” “above,” “below,” “top,” “bottom,” “upper” and “lower” may be used to describe the various elements' relationships to one another, as illustrated in the accompanying drawings. These relative terms are intended to encompass different orientations of the device and/or elements in addition to the orientation depicted in the drawings. For example, if the device were inverted with respect to the view in the drawings, an element described as “above” another element, for example, would now be below that element.
- Relative terms may be used to describe the various elements' relationships to one another, as illustrated in the accompanying drawings. These relative terms are intended to encompass different orientations of the device and/or elements in addition to the orientation depicted in the drawings.
- The term “microorganism” or “microbe,” as used herein, refers to a small (often, but not always, microscopic) organism that is typically, but not exclusively, single cellular, and includes organisms from the kingdoms bacteria, archaea, protozoa, and fungi. Viruses are also classified as microorganisms in the present disclosure document even though they are not living organisms by themselves.
- The apparatus and method will first be described with reference to a representative embodiment for performing airborne virus detection in an example application in which the virus being detected is influenza. The apparatus and method will then be described with reference to a representative embodiment for detecting non-airborne viruses in an example application in which the virus being detected is the Zika virus. Data is also disclosed herein of experiments that were conducted using the method and apparatus to detect coronaviruses, and in particular, SARS-CoV-2. All of the representative embodiments described herein are capable of being implemented as portable, rapid, reliable and cost-effective diagnostic POC tools that can be operated without the need for lab equipment and with very little human intervention. Accordingly, the apparatuses and methods are well suited for, but not limited to, use in resource-limited regions.
- The aerosol transmission route is one of the three major transmission routes of airborne infectious diseases. However, the dynamics and significance of the aerosol transmission route are not well understood, nor does there exist an automatic, efficient and realistic biosensor for detecting small-sized virus aerosols. As discussed above, the assignee's VIVAS is a water-vapor-based condensational growth system capable of collecting aerosolized particles (e.g., from 8 nm to 10 μm in size). In accordance with a representative embodiment described herein, the apparatus includes 3D-printed sample preparation components and a laminated paper-based RNA amplification component, referred to hereinafter collectively as the “SPRA” apparatus. In accordance with the representative embodiment, the SPRA apparatus is designed to integrate with the VIVAS to perform a rapid, sample-to-answer virus aerosol detection based on the RT-LAMP. The integrated SPRA apparatus and VIVAS is referred to hereinafter as the “integrated SPRA-VIVAS platform.”
- The 3D-printed sample preparation component of the SPRA apparatus includes an innovative “bearing ball valve” capable of storing and delivering reagents without manually pipetting. The inventors have tested the sensitivity of the SPRA apparatus to detect 1 TCID50 H1N1 flu viruses spiked in 140 μL aqueous sample, which is more sensitive than the commercial FTA® card and Whatman™ glass microfiber. Using the integrated SPRA-VIVAS platform, the inventors have demonstrated the successful detection of lab-generated H1N1 flu virus aerosols in less than one hour. The results demonstrate that the SPRA-VIVAS platform has a great potential in airborne infectious disease screening and monitoring during outbreaks. The effective sampling and rapid detection of virus aerosols also facilitates a better understanding of the significance of aerosol transmission mode in airborne infectious disease outbreaks.
- As indicated above, in accordance with a representative embodiment, the RT-LAMP is integrated with the VIVAS, with the RT-LAMP being used to detect the virus aerosols that are collected by the VIVAS. The RT-LAMP is an isothermal DNA amplification technique with high robustness, sensitivity and specificity. With its short incubation time and simplified thermal management, RT-LAMP can be easily employed by POC platforms. For RNA extraction from the collected virus aerosols, in accordance with a representative embodiment, a laminated paper-based device is used for extraction. Compared to analytical devices made of other materials, paper-based devices have the advantages of being extremely low-cost, flexible, easy to dispose and capable of pumping liquid using capillary forces. In accordance with an embodiment, 3D-printed components are used to house the laminated paper-based device and the RNA extraction reagents. In accordance with a representative embodiment, an innovative valving mechanism inspired by the small animal water bottle is employed to conduct RNA extraction without the help of even basic lab equipment such as a pipette. The 3D-printed components allow the laminated paper-based device to be combined with the VIVAS, so that the aerosols collected by the VIVAS can be directly impinged onto the RNA extraction pad.
-
FIGS. 1A-1E illustrate top perspective views of theSPRA apparatus 1 in accordance with a representative embodiment in its partially-disassembled state to reveal features of the various components of theSPRA apparatus 1 that would not be visible in the fully-assembled state.FIG. 1A shows thedetection unit 2, which, in accordance with this representative embodiment, is a laminated paper-based RNA amplification device referred to hereinafter as “the paper-basedRNA amplification device 2.” Apaper pad 2 a of thedevice 2 is laminated between two layers ofthermoplastic films device 2 in the manner in which a common identification card is fabricated.FIG. 1B shows the paper-basedRNA amplification device 2 attached to apolycarbonate container 3 via anadhesive tape 4.FIG. 1C shows a cross-sectional side view of the mechanism of the bearingball valve 5 of the SPRArotatable reservoir unit 6. Thevalve 5 is actuated by apillar 7 of theSPRA collector 8 pushing thebearing ball 9 up to discharge the liquid housed in the reservoir.FIG. 1D shows theSPRA apparatus 1, which includes theSPRA collector 8 and abuffer unit 6. - In accordance with this representative embodiment, the
buffer unit 6 is a rotatable buffer unit referred to hereinafter as “the SPRArotatable reservoir unit 6.” The SPRArotatable reservoir unit 6 and theSPRA collector unit 8 are assembled together via apin 11. Thus, the SPRArotatable reservoir unit 6 is rotatably coupled to theSPRA collector 8. The rotatableSPRA reservoir unit 6 includes three reservoirs to separately house the binding buffer and the two wash buffers. TheSPRA collector 8 functions as a sample collector with the laminated paper-basedRNA amplification device 2 attached underneath.FIG. 1E shows a lure-lock-threadedlid 13 of the SPRArotatable reservoir unit 6 with an O-ring used to prevent liquid leakage during transportation. A protruded peg underneath thelid 13 is designed to press down the bearing ball once thelid 13 is tightened, as will be described below in more detail. - Three of the
lids 13 of different sizes are used to seal thebinding buffer 6 a and the twowash buffers rotatable reservoir unit 6 to prevent spillage during transportation. The design can be the same for all of the lids, but lids of the wash buffers 6 b and 6 c are smaller in diameter than the lid of thebinding buffer 6 a. Securing the lids to therespective buffers 6 a-6 c causes the ball bearing valves of thebuffers 6 a-6 c to be locked in the closed positions. -
FIGS. 2A-2F are top perspective views of theSPRA apparatus 1 and theVIVAS 12 at various stages during use. TheSPRA collector 8 is mechanically coupled to the bottom of theVIVAS 12 by a 3D-printeddevice holder 14. The detection scheme for viruses collected from aerosols is as follows. The virus particles in the aerosol are enlarged by theVIVAS 12 and impinged directly into the lysis buffer housed in the reservoir of theSPRA collector 8, as shown inFIG. 2A . After a 15-minute collection period, theSPRA collector 8 was removed from theVIVAS 12 and assembled with the rotatableSPRA reservoir unit 6, as shown inFIG. 2B . The rotatableSPRA reservoir unit 6 was then rotated to discharge thebinding buffer 6 a into the virus lysate held in theSPRA collector 8. The laminated paper-basedRNA amplification device 2 underneath theSPRA collector 8 filtered the virus RNA from the lysate. Once the lysate filtration process was completed, the rotatableSPRA reservoir unit 6 was rotated to discharge the twowash buffers FIGS. 2C and 2D . The whole RNA purification process took around 25 minutes, depending on the collected volume. The laminated paper-basedRNA amplification device 2 was then peeled from thecollector 8 and taped onto thepolycarbonate container 3 for RT-LAMP amplification. After a 25-minute incubation period, as depicted inFIG. 2E , the amplified DNA could be detected using 1 μL SYBR Green dye and a blue LED flashlight, as shown inFIG. 2F . -
FIG. 3A shows a top-view photograph of the rotatableSPRA reservoir unit 6 shown inFIGS. 1D and 1E .FIG. 3B shows top-view and bottom-view photographs of the rotatableSPRA reservoir unit 6 with thelids 13 attached to therespective buffers 6 a-6 c.FIG. 3C shows a side-view photograph of theVIVAS 12 having the device holder 14 (FIG. 2A ) mechanically coupled to the bottom of theVIVAS 12. As indicated above with reference toFIG. 2A , thedevice holder 14 couples theSPRA collector 8 to theVIVAS 12.FIG. 3D shows a top-view photograph of thedevice holder 14 holding theSPRA collector 8.FIG. 3E shows a bottom-view photograph of thedevice holder 14. - Virus and its Preparation
- The following is a discussion of an experiment that was conducted using the integrated SPRA-VIVAS platform described above with reference to
FIGS. 1A through 3E . MDCK (CCL-34; Madin-Darby Canine Kidney Epithelial Cells) were obtained from the American Type Culture Collection (Manassas, Va., USA) and were propagated as monolayers at 37° C. and 5% CO2 in Advanced Dulbecco's Modified Eagle's Medium (aDMEM) (Invitrogen, Carlsbad, Calif., USA) supplemented with 2 mM L-Alanyl-L-Glutamine (GlutaMAX, Invitrogen), antibiotics (PSN; 50 μg/mL penicillin, 50 μg/mL streptomycin, 100 μg/mL neomycin (Invitrogen)), and 10% (v/v) low IgG, heat-inactivated gamma-irradiated fetal bovine serum (HyClone, Logan, Utah). - Prior to use, all cell lines were treated for 3 weeks with plasmocin and verified free of mycoplasma DNA by PCR. T75 flasks of newly confluent MDCK cells were infected with 100 μL of Influenza Virus A/Mexico/4108/2009 (pH1N1), a wild-type H1N1 pandemic 2009 strain, in 5 mL of serum-free aDMEM supplemented as previously described plus L-1-tosylamido-2-phenylethyl chloromethyl ketone (TPCK)-treated mycoplasma-free and extraneous virus-free trypsin (Worthington Biochemical Company, Lakewood, N.J.) and incubated in 5% CO2 at 33° C. The TPCK trypsin was used at a final concentration of 2 μg/mL for MDCK. After 4 hours of incubation, 3 mL of serum-free aDMEM supplemented with TPCK trypsin was added. After CPE were observed in over 50% of cells, the cells were scraped, and the virus was collected and frozen at −80° C. A virus stock solution of 6.4×106 TCID50/mL was used for sample spiking and RNA extraction.
- RNA was extracted from 140 μL of H1N1 flu virus samples using a QIAamp Viral RNA Mini Kit (QIAGEN, Valencia, Calif., USA) following manufacturer's protocol. The collected RNA was eluted with 60 μL of buffer AVE (QIAGEN) and stored at −80° C. before use. RNA extracted from H1N1 flu virus was used to conduct reverse transcriptase loop-mediated isothermal amplification (RT-LAMP). Each 25 μL RT-LAMP system contains 2.5 μL of 10× isothermal amplification buffer, 1.4 mM dNTPs, 6 mM MgSO4, 2.5 of 10× primer mix, 8 U Bst 2.0 WarmStart® DNA Polymerase, 7.5 U WarmStart® RTx Reverse Transcriptase, and 1 μL RNA sample. Except for the dNTPs from ThermoFisher Scientific (MA, USA), other reagents in the RT-LAMP system was obtained from New England Biolabs (Ipswich, Mass., USA). The primer mix contains 1.6 μM F1P/B1P, 0.2 F3/B3, and 0.4 μM LF/LB. The sequences of possible primers are listed below in Table 1. The inventors followed the primer designs in the literature; they used the first set of primers though other sets of primers can be used as will be understood by those of skill in the art in view of the description provided herein. These primers were obtained from Integrated DNA Technologies (Coralville, Iowa, USA). To perform the amplification, the RT-LAMP system was incubated at 63° C. for 30 minutes in a Bio-Rad Mycycler® (Bio-Raid, CA, USA). The amplicons were confirmed with 2% agarose gel electrophoresis. Gel bands were imaged using a Gel Doc™ EZ system (Bio-Rad).
-
TABLE 1 Possible sequences of RT-LAMP primers for H1N1 flu virus detection Primer Sequence (5′-3′) Ref. F3 ACCTTCTAGAAGACAAGCATAA 1 B3 TCCTCATAATCGAT FIP TGGATTTCCCAGGATCCAGCGGAAACTATGCAAACTAAGAGG BIP TCCACAGCAAGCTCATGGTCTCCTGGGTAACACGTTCC LF CCAAATGCAATGGGGCTAC LB CTACATTGTGGAAACATCTAGTTCAG F3 AGACGCTTTGTCCAAAATGC 2 B3 TCACAAGTGGCACACACTAG FIP CCTTGGCCCCATGGAACGTTATGGGGACCCGAACAACATG BIP TTCAACTGGTGCACTTGCCAGTGTGGTCACTGTTCCCATCC LF TGAGCTTCTTGTATAGTTTAACTGC LB TGCATGGGCCTCATATACAACA F3 AAGCTCAGCAAATCCTACA 3 B3 TCCCTCACTTTGGGTCTT FIP GACTTTGTTGGTCAGCACTAGTAGAAAAGGGAAAGAAGTCCTCG BIP TCTATCAGAATGCAGATGCATATGTTGCTATTTCCGGCTTGAA LF GATGGTGAATGCCCCATAGC LB TTTTGTGGGGTCATCAAGATACAG F3 AAGCTCAGCAAATCCTACA 4 B3 TCCCTCACTTTGGGTCTT FIP GACTTTGTTGGTCAGCACTAGTAGATTTTAAAGGGAAAGAAGTCCTCG BIP TCTATCAGAATGCAGATGCATATGTTTTTTGCTATTTCCGGCTTGAA LF GATGGTGAATGCCCCATAGC LB TTGTGGGGTCATCAAGATACAGC F3 CAGACTAGGCAGATGGTAC 5 B3 TCAGGTGCAAGATCCCAATG FIP GCCTGCAAATTTTCAAGAAGGTCTTTTGCAATGAGAACTATTGGGACTC BIP CCAGAAGCGAATGGGAGTGCTTTTATTTGCTGCAATGACGAGAG LF AGACCAGCACTGGAGCTAGG LB GATGCAGCGATTCAAGTGATC F3 CCGGGAGACAAAATAACATTC 6 B3 GTATATTCTGAAATGGGAGGC FIP CAGATCCAGCATTTCTTTCCATTGGAAGCAACTGGAAATCTAGTG BIP TATCATTTCAGATACACCAGTCCACTGGTGTTTATAGCACCCTTG LF CGAATGCATATCTCGGTAC LB ATACAACTTGTCAAACACC Note: FIP stands for Forward Inner Primer; BIP stands for Backward Inner Primer; LF and LB are the forward and backward loop primers. - To verify the incubation time required for the H1N1 flu virus RT-LAMP primers, a real-time RT-LAMP assay was carried out. To enable real-time amplicon detection, 0.5 of 10× concentrate SYBR green I nucleic acid gel stain in DMSO (ThermoFisher Scientific) and 0.5 μL ROX reference dye (ThermoFisher Scientific) were added to the 25 μL RT-LAMP reaction buffer. The fluorescence signal was read through the
QuantStudio 3 real-time PCR system (ThermoFisher Scientific). - The laminated paper-based RNA amplification device 2 (
FIGS. 1A and 1B ) contains a polycarbonate container, a double-sided adhesive tape, and a laminated paper pad. Three kinds of paper materials, the FTA® classic card (ThermoFisher Scientific), theWhatman™ 1 Chr chromatography paper (ThermoFisher Scientific), and the Whatman™ GF/F glass microfiber filter (ThermoFisher Scientific) were studied for fabricating the paper-based RNA isolation device. A 3.5-mm-diameter round pad of the paper material was made using a steel puncher. Two layers of thermoplastic films were shaped by cutting a section of 75 μm thick polyester thermal bonding lamination films (Lamination Plus, Kaysville, Utah, USA) using a Graphtec Craft Robo-S cutting plotter (Graphtec Corporation, Yokohama, Japan). To laminate the device, the paper pad and the top and bottom films were aligned and passed through a heated laminator (GBC® Catena 65 Roll Laminator, GBC, Lake Zurich, Ill., USA), which was set at a rolling speed of “1” with the temperature at 220 T. After lamination, the laminated paper pad was attached to a 3 mm thick, 2 cm×2 cm square polycarbonate container via a piece of 3M 9087 white bonding tape (R. S. Hughes, Sunnyvale, Calif.) to form the final device. The container was shaped from a piece of clear polycarbonate sheet (McMaster-Carr, Elmhurst, Ill.) using a milling machine (Sherline Products, Vista, Calif.). A 3-mm-diameter round hole was made in both the polycarbonate container and the double-sided adhesive tape to align with the paper pad as a sample loading port. - The lysis product mixture of H1N1 flu virus was used to test the performance of laminated paper-based RNA amplification device. Aliquots containing 10, 1, and 0.1 TCID50 H1N1 flu virus lysis per μL were made with the flu virus stock solution and molecular-biology-grade water and buffer AVL (QIAGEN) at the ratio of 1:4 and stored at −80° C. before use. To compare the RNA capture efficiency of laminated paper-based RNA amplification device made of FTA® card, chromatography paper and glass microfiber paper, a series dilution of 70 μL H1N1 flu virus lysis (made from virus spiked water and AVL lysis buffer in the ratio of 1:4) was used to compare the limit of detection (LOD) of each material. An ethanol (200 proof) solution of 56 μL was mixed into the diluted virus lysis before introducing to the device. A solution of 100 μL each AW1 (QIAGEN) and AW2 (QIAGEN) of 100 μL each was then filtered through the paper pad sequentially to purify the RNA captured by the device.
- To detect the RNA captured, a piece of adhesive tape (Fellows)° 4 (
FIG. 1B ) was attached to the bottom of the device 2 (FIGS. 1A and 1B ), and 25 μL RT-LAMP amplification buffer was loaded to the paper pad. Thedevice 2 was then sealed with another piece of adhesive tape on the top. The sealed device was incubated at 63° C. for 25 minutes in an Isotemp 105 water bath (ThermoFisher Scientific) for DNA amplification. The amplicons were analyzed with gel electrophoresis as described above. - As indicated above, in accordance with an embodiment, 3D-printed sample preparation components were designed to incorporate the laminated paper-based
RNA amplification device 2 to form thefinal SPRA apparatus 6. These components could be used to perform viral RNA purification without using lab tools such as a pipette, for example. The sample preparation components were fabricated with a commercial 3D printer, Ultimaker 3 (Ultimaker, Geldermalsen, Netherlands), using polylactic acid (PLA) filament with polyvinyl alcohol (PVA) as support material. It should be noted, however, that the inventive principles and concepts are not limited to these components being formed via 3D printing, as will be understood by those of skill in the art in view of the description provided herein. Alternatives to 3D printing for making these parts include molding, milling, machining, and other manufacturing and fabrication methods. - The print layer height was set to 0.06 mm and the infill density was set to 100%. As shown in
FIG. 1D , the 3D-printed sample preparation components contain two units. The SPRArotatable reservoir unit 6 comprises thebuffer reservoir 6 a housing the binding buffer (molecular-biology grade ethanol) and the two wash buffers (AW1 & AW2, QIAGEN) 6 b and 6 c for RNA purification. The bottom unit of theSPRA apparatus 1 is theaforementioned SPRA collector 8 where the laminated paper-basedRNA amplification device 2 was attached with a piece of double-sided tape. TheSPRA apparatus 1 was assembled by inserting thepin 11 through one hole located in each unit. A photo of theSPRA apparatus 1 compared to a U.S. quarter is shown inFIG. 3A . - A simple fluid control valve, the “bearing ball” valve shown in
FIG. 1C , was employed to trigger the release of buffers from thebuffer reservoirs 6 a-6 c to theSPRA collector 8 of theSPRA apparatus 1. The valve was inspired by the small animal water bottle in which water flowed out when a drinking animal pressed against the bearing ball blocking the water dispensing tube. As shown inFIG. 1C , a 5/16-inch-diameter opening was designed at the bottom of the funnel-shapedreservoirs 6 a-6 c to house a stainless-steel bearing ball 9. The opening was designed in such a way that the bearing ball could block the opening while protruding 2 mm from the bottom of the buffer reservoir. The bearingball 9 functioned as a plug to keep the liquid from flowing out. The bearing ball valve could be triggered by rotating the reservoir unit until the ball was pushed up by a pillar 7 (FIG. 1D ) in the center of thecollector 8. To prevent possible reagent contamination during transportation, the lid 13 (FIGS. 1E and 3B ) with a lure-lock thread and a piece of O-ring (McMaster-Carr) was used. Thelid 13 contained a peg underneath that pressed against the bearingball 9 while the thread was tightened. Thelid 13 achieved a leak-free seal when the device was rotated upside down. - The aforementioned H1N1 flu virus was used for virus aerosol generation and testing. All the sampling experiments were performed in a US Department of Agriculture inspected-and-approved BSL2-enhanced laboratory following BSL3 work practices. To generate flu virus aerosols, 10 mL of 1×105 TCID50/mL H1N1 flu virus solution in phosphate-buffered saline (PBS) plus 0.5% (w/v) bovine serum albumin (BSA) fraction V was used with a 6-jet BioAerosol Nebulizing Generator (BANG, CH Technologies).25-27 HEPA-filtered room air was used to provide air flow for the BANG.
- The VIVAS 12 (
FIGS. 2A and 3C ), a laminar-flow, water-based condensational growth system, was used to amplify the virus aerosols generated by the BANG and has been described previously. To integrate theSPRA apparatus 1 with theVIVAS 12, thedevice holder 14 was designed to fixate, or mechanically couple, theSPRA collector 8 to the VIVAS' aerosol outlet with four screws. A rubber pad was used to form an air-tight seal to prevent aerosol leakage during sampling (FIG. 3C ). Fluorescein aerosols were used to demonstrate the collection result. As shown inFIG. 3E , the collected droplets deposited by the 32 nozzles of the VIVAS could be observed in theSPRA collector 8. - As described previously, the conditioner (the top half) of the
VIVAS 12 was cooled to 6° C., and the initiator (the bottom half) was heated to 45° C. An air flow rate at six liters per minute (LPM) was introduced into theVIVAS 12. A negative control sample was first collected with 10 mL PBS plus 0.5% (w/v) BSA in the BANG for 15 minutes. Three positive collections with virus solution in the BANG were performed for 15 minutes each. A lysis buffer (buffer AVL) of 560 μL was preloaded to theSPRA collector 8 where the aerosols from theVIVAS 12 directly impinged. The lysis buffer protected viral RNA from RNase degradation and deactivated the collected virus to reduce the generation of biohazardous wastes. Between each collection, a washing step consisting of 5-minute collection of 0.01% sodium dodecyl sulfate (SDS, ThermoFisher Scientific) solution in the BANG and then 25-minute collection of molecular-biology grade water in BANG was performed to flush the virus aerosols in the system from a previous sampling. - After the 15-min sampling period, the SPRA collector was removed from the
VIVAS 12 by loosening screws and assembled with the top reservoir unit 6 (FIG. 1D ). The assembledSPRA apparatus 1 was first placed on top of a piece of blotting paper to provide capillary forces for the RNA purification process. Thebinding buffer 6 a (560 μL ethanol) was discharged right after to enhance RNA binding to the laminated paper pad. The blotting process took roughly 15 minutes, depending on the volume of sample collected and the type of absorbent used. After all the lysate was filtered through the laminated paper pad, thereservoir unit 6 of theSPRA apparatus 1 was rotated to add thefirst wash buffer 6 b (250 AW1) to thecollector 8, and thetop reservoir unit 6 was rotated again, and thesecond wash buffer 6 c (250 μL AW2) was discharged and filtered through in the same manner. The two wash steps took roughly 5 minutes to complete. - To detect the purified RNA from the virus aerosols, the laminated paper-based
RNA amplification device 2 was peeled from theSPRA collector 8 and taped to its polycarbonate container 3 (FIG. 1B ) to conduct RT-LAMP amplification as described previously. After 25 minutes incubation, 1 μL of 10,000× concentrate SYBR green I nucleic acid gel stain was added to the amplicons, and the results can be read by a naked-eye. Alternatively, an ULAKO blue LED flashlight (Amazon, Wash., USA) (FIG. 2F ) powered by an AA battery was used to excite the green fluorescence from the amplicon-SYBR complexes. The resulting color of the solution was imaged using a smart phone. A piece of brown-tainted translucent plastic film was taped in front of the phone camera lens to filter out the excess blue light from the LED flashlight. It should be noted that other light sources such as lamps and various diodes, for example, can be used for this purpose, as will be understood by those of skill in the art in view of the description provided herein. -
FIG. 4A is a graph showing curves 16, 17, 18 and 19 representing normalized fluorescent signals of 10, 100, 1000 and no-temperature control (NTC), respectively, TCID50 H1N1 flu virus genome equivalents as a function of RT-LAMP time. The curves 16-19 indicate that all samples' amplification signals reached the plateau in 20 minutes.FIG. 4B is a plot of a standard curve (log TCID50 per reaction vs. threshold time) generated with three replicates of each serial diluted H1N1 flu virus RNA samples. The QIAamp Viral RNA Mini Kit (QIAGEN) was used as a bench top standard to purify RNA from aqueous samples spiked with H1N1 flu virus. Fluorescence readings were taken from RT-LAMP containing 10, 100 an(a) d 1000 TCID50 RNA equivalents using theQuantStudio 3 real-time PCR system (FIG. 4A ). All the wells containing flu virus RNA were observed with a signal within 20 minutes, and no non-specific amplification was observed during the 30-minute incubation period. This result suggested that a 25-minute incubation was sufficient to detect the flu virus RNA isolated by our device. The linear-shaped standard curve (FIG. 4B ) indicated that quantitative virus aerosol detection can be achieved by the integrated SPRA-VIVAS platform with portable optical sensors. - The laminated paper-based
RNA amplification device 2 used in the experiment was made as follows. A lamination technique was used to prepare a piece of paper pad so that it could be used as a filter for RNA in the same manner of the commercially available nucleic acid purification spin column. The chaotropic-salt-based buffers from QIAamp Viral RNA Mini Kit (QIAGEN) was used to improve RNA binding to the paper substrate. The polycarbonate container 3 (FIG. 1B ) was attached to the laminated paper pad as a sample well to form the paper-based RNA amplification device. Instead of centrifugation force, sample filtration was powered by capillary forces generated in porous paper and the absorbent pad beneath the paper-based RNA amplification device. H1N1 flu virus was used to demonstrate RNA purification and amplification in thedevice 2. The amplicons were analyzed using agarose gel electrophoresis and ethidium bromide staining. - To select an effective binding material for RNA, devices were fabricated using FTA® card, the Whatman™ Chr chromatography paper, and the Whatman™ GF/F glass microfiber filter for comparison. The FTA® card is a commercialized filter paper specifically treated to extract, bind, and preserve nucleic acids from blood, plant and animal tissue extracts and other sources according to the manufacturer. The chromatography paper is an untreated, high quality cellulose fiber paper. The GF/F glass microfiber filter is a paper specifically designed for nucleic acid purification. Paper-based devices made of FTA® card, glass microfiber and chromatography paper were tested with different concentrations of H1N1 virus lysis to compare the limit of detection (LOD). The results indicated that the device made of chromatography paper had the lowest LOD, detected spiked samples of 0.8 TCID50 flu virus, while the device made of FTA® card and glass microfiber detected 5 TCID50.
- Untreated cellulose has been used as a nucleic acid isolation material since the 1960s, though its use is far less common than silica. This is possibly due to the complicated steps of assembling cellulose powder into a column often involved. Those manual steps make the cellulose powder less desirable compared to the ready-to-use silica column. The laminated paper-based
RNA amplification device 2, on the other hand, is easy to make, of low cost, and does not require complicated manual steps during usage. The result discussed above suggests that the cellulose chromatography paper has a great potential as a RNA extraction substrate. As a result, all of the following experiments were performed using devices made from chromatography paper. It should be noted, however, that the inventive principles and concepts are not limited to using any particular type of extraction/amplification device for this purpose. - A H1N1 flu virus spiked water of 140 μL was lysed with 560 μL buffer AVL and tested with the
SPRA apparatus 1 to evaluate its performance in handling samples with the same volume range of those collected by theVIVAS 12 at 6 LPM for 15 minutes. The volume ratio of sample-lysis-ethanol was kept at 1:4:4 as instructed by the QIAamp Viral RNA mini Kit's manufacturer. - The RNA purification and amplification process each took roughly 25 minutes to complete, after which the result could be read using SYBR green dye and blue LED flashlight without lab instruments. As shown in
FIGS. 5A-5C , 1 TCID50 H1N1 flu virus per 140 μL sample was successfully detected in one hour using theSPRA apparatus 1. The SYBR green-DNA-complex absorbs blue light and emits green light, resulting in a light-yellow color (FIG. 5A ) when observed under the ambient light and a bright green fluorescence under blue LED (FIG. 5B ). SYBR green was chosen for the experiment as it detects the DNA amplicons directly, while other colorimetric RT-LAMP methods such as the hydroxynaphthol blue, the leuco crystal violet, and the phenol red39 detect the by-products of DNA amplification. - The average collection volume of the integrated SPRA-VIVAS system for a 15-minute sampling using 10 mL PBS/BSA media in the BANG and 6 LPM air flow rate for the VIVAS was determined by weighing the
SPRA collector 8 before and after collection to be 143±25 μL (mean±standard deviation). As a result, 560 μL lysis buffer was used in theSPRA collector 8 for the H1N1 flu virus aerosol detecting experiment. A virus concentration of 1×105 TCID50/mL H1N1 flu virus in PBS/BSA was used in the BANG and sampled in triplicates. According to the infectious H1N1 virus collection efficiency reported by the inventors in literature, the amount of collected H1N1 flu virus is above the sensitivity of theSPRA apparatus 1. - The
SPRA apparatus 1 successfully detected the H1N1 flu virus aerosols generated in lab (FIGS. 6A-6C ). No nonspecific amplification was observed in the negative control collection of PBS/BSA aerosols. Strong fluorescence signals were observed from all the triplicates of the H1N1 flu virus aerosol collections. Including the sampling time, one virus aerosol detection process only took around 65 minutes to complete, proving theSPRA apparatus 1 to be fast and effective in assessing airborne influenza virus transmission risks and/or in screening the presence of a certain type of airborne virus in the environment. - The integrated SPRA-VIVAS platform detected lab-generated H1N1 flu virus aerosols in one hour. This system features a two-step concentration for the sporadic virus aerosols: (a) the concentration of liters of virus aerosols into a 150 μL aqueous sample, and (b) the filtration of lysed virus aerosol RNA onto the laminated paper pad. The two-step concentration provides the platform with the sensitivity required to detect virus aerosols using a rapid, specific RT-LAMP method. Moreover, the laminated paper-based
RNA amplification device 2 used as a filter was able to process a flexible amount of collected aerosol sample, thus allowing the sensitivity to be increased by increasing the collection time, i.e., the volume of aerosol collected by theVIVAS 12, if necessary. - The detection limit of the SPRA-VIVAS platform can be explored using virus aerosols of different concentrations and a portable optical sensor for quantitative detection. The collection of real-world virus aerosols can also be performed in places such as infirmaries and classrooms. On the other hand, the superior sensitivity and high portability of the
SPRA apparatus 1 in RNA virus detection over the commercial FTA® card and Whatman™ glass microfiber has been demonstrated herein. Except for detecting collected virus aerosols, theSPRA apparatus 2 can also be used to detect virus from other types of aqueous samples. - Having described the SPRA apparatus and method for performing airborne virus detection in accordance with a representative embodiment, the apparatus and method for detecting non-airborne viruses will now be described with reference to a representative embodiment and an example application in which the virus being detected is the Zika virus.
- In the following description, a valve-enabled lysis, paper-based RNA enrichment, and RNA amplification device (VLEAD) apparatus and method for sample-to-answer Zika virus detection are presented. It should be noted, however, that the VLEAD apparatus and method are suitable for providing sample-to-answer virus detection for viruses other than the Zika virus. In accordance with a representative embodiment, the VLEAD apparatus comprises 3D-printed components for sample preparation and a laminated paper pad for RNA enrichment. The valving mechanism described above with reference to
FIG. 1C is incorporated into the VLEAD apparatus design to enable RNA extraction to be conducted without the help of even basic lab equipment such as a pipette. Instead of choosing popular paper materials such as the FTA® card, in accordance with a representative embodiment, untreated, cellulose chromatography paper is used as an RNA binding material to reduce the fabrication cost and potential inhibitory effect on RT-LAMP amplification. - In accordance with a representative embodiment, RT-LAMP amplification is performed using a commercially available, controllable, battery powered “smart” coffee mug (Ember™ Travel Mug) as a water bath to heat the device. A variety of portable electrical and chemical heaters have been developed for POC diagnostic devices using isothermal DNA amplification, but they are often not readily available to average users and thus require further fabrication and calibration. On the other hand, the Ember™ coffee mug is carried by many Starbucks® coffee shops in the U.S. and major online vendors such as Amazon and eBay, and its temperature can be accurately controlled using a smartphone software application program (App). For naked-eye result reading, in accordance with a representative embodiment, a SYBR green dye and a relatively inexpensive blue LED flashlight are used to get an explicit fluorescence signal from the positive test.
- The duration Zika virus can be detected in blood, saliva, urine and semen ranges from days to months after symptom onset. To demonstrate some of the inventive principles and concepts, the inventors have chosen urine and saliva to demonstrate that the sample collection processes performed using the VLEAD apparatus and method are simple and non-invasive. The inventors also used Zika virus spiked water to compare the sensitivity of the VLEAD apparatus with a commercial QIAamp Viral RNA mini Kit (QIAGEN). After validating the VLEAD apparatus and method using Zika virus spiked samples, the inventors successfully detected Zika virus in a clinical urine sample collected in 2016.
-
FIGS. 7A-7D are perspective views of components comprising theVLEAD apparatus 20 in accordance with a representative embodiment. As shown inFIGS. 7A-7D , theVLEAD apparatus 20 comprises three parts, namely, a buffer unit 21 (FIG. 7A ), a collector or mixing unit 22 (FIG. 7B ) (referred to hereinafter as “the mixingunit 22”), and a detection unit 23 (FIG. 7C ), which may be identical to paper-basedRNA amplification device 2 shown inFIG. 1A . The mixingunit 22 is integrated with thedetection unit 23 by inserting the bottom protrusion 28 (FIG. 7B ) of the mixingunit 22 into thecenter hole 26 in thedetection unit 23 with a piece of double-sided adhesive tape disposed between the two units being used to fix them together. - In accordance with this representative embodiment, the
buffer unit 21 is slidably coupled with the mixingunit 22 via a slidingmechanism 27. In accordance with a representative embodiment, the slidingmechanism 27 comprises a pair ofrails 27 a on the mixingunit 22 that engages a pair ofgrooves 27 b on thebuffer unit 21. - A commercial 3D printer, the Ultimaker 3 (Ultimaker, Geldermalsen, Netherlands) was used to fabricate the
buffer unit 21 and the mixingunit 22. The devices were printed from polylactic acid (PLA) with polyvinyl alcohol (PVA) as support material. The print layer height was set to 0.06 mm and the infill density was set to 100%. Both thebuffer unit 21 and the mixingunit 22 can also be made by injection molding, machining, and other methods, as will be understood by those of skill in the art in view of the description provided herein. - The
detection unit 23 contained a polycarbonate container, a double-sided adhesive tape, and a laminated paper pad. To fabricate the laminated paper pad, a 3.5-mm-diameter circle of theWhatman™ 1 chromatography paper (Fisher Scientific, Pittsburgh, Pa., USA) was made using a steel puncher. Two layers of thermoplastic films were shaped by cutting a section of 75 μm thick polyester thermal bonding lamination films (Lamination Plus, Kaysville, Utah, USA) using a Graphtec Craft Robo-S cutting plotter (Graphtec Corporation, Yokohama, Japan). The paper pad and the cover and bottom films were then aligned and passed through a heated laminator (GBC® Catena 65 Roll Laminator, GBC, Lake Zurich, Ill., USA), which was set at a rolling speed of “1” with the temperature at 220° F. - After lamination, the laminated paper pad was attached to a 3 mm thick, 2 cm-by-2 cm square polycarbonate container via a piece of 3M 9087 white bonding tape (R. S. Hughes, Sunnyvale, Calif.) to form the RNA detection unit. The container was shaped from a piece of clear polycarbonate sheet (McMaster-Carr, Elmhurst, Ill.) using a milling machine (Sherline Products, Vista, Calif.). A photo of the device is shown in
FIGS. 8(a) and (b) with a quarter as a comparison in size. - Fluid control valves 31 (
FIG. 7D ), that are identical to the fluid control valve shown inFIG. 1D in accordance with this representative embodiment, are disposed in thebuffer unit 21 for triggering the release of buffers from thebuffer unit 21 into the reservoir 22 a of the mixingunit 22. As shown inFIG. 7D , a 4-mm-diameter opening 29 was designed at the bottom of the funnel-shapedreservoirs 21 a-21 d of thebuffer unit 21 to house a stainless-steel bearing ball 24. Thisopening 29 was designed in a way that the bearingball 24 blocks the opening while protruding 1.5 mm from the bottom of thebuffer reservoirs 21 a-21 d. Tworectangular gaps 22 b are formed in awall 22 c of the mixingunit 22 so that the bearing ball can pass through while thebuffer unit 21 slides along the mixingunit 22. The bearingball 29 functions as a plug to keep the buffer from flowing out of thereservoirs 21 a-21 d until the bearingball 29 is pushed up by thepost 25 of the mixingunit 22 when the mixingunit 22 is sliding along thebuffer unit 21. -
FIGS. 8A-8C are photographs of the apparatus shown inFIGS. 7A-7D and its components. To prevent accidental triggering of thefluid control valves 31 during device transportation and storage, a sealing system was employed using wax and cover film to seal the buffer unit 21 (FIG. 8C ). A small amount of Akrowax™ 130 (Akrochem, Akron, Ohio, USA) was placed at the bearingball 24 to melt and re-solidify, so that it could form a breakable bond between the bearingball 24 and thebuffer unit 21. The bottom of thebuffer unit 21 was further protected by sliding it into a device holder 35 (FIG. 8C ). After loading the required buffers, a piece of polycarbonate film was taped to the top of thebuffer unit 21 via double-sided adhesive to prevent buffer evaporation and spillage, and then thebuffer unit 21 coupled to the device holder 35 (FIG. 8C ) was ready for shipping and/or long-term storage. - Vero E6 (CRL-1586; African green monkey kidney epithelial cells) were obtained from American Type Culture Collection (ATCC, Manassas, Va., USA) and cultured in Advanced Dulbecco's Modified Eagle's medium (aDMEM) with 10% low antibody, gamma-irradiated, heat inactivated fetal bovine serum (FBS), GlutaMAX, and Penicillin-Streptomycin-Neomycin (PSN) at 37° C. with 5% CO2.
- A Zika virus (ZIKV) strain from Puerto Rico (PRVABC59) was obtained from Biodefense and Emerging Infections Research Resources Repository (BEI Resources, Manassas, Va., USA). The strain was grown up for a lab stock by inoculating 475 μL media (aDMEM with 3% FBS, GlutaMAX, and PSN) with a ratio of 25 μL virus to a monolayer of Vero E6, and gently rocking once every 15 minutes at 37° C. with 5% CO2 for 1 hour. A T25 (25 cm2 growth surface) flask with Vero E6 cells at 60% confluency was used for observation of ZIKV-induced cytopathic effects (CPE). After allowing for virus adsorption for two hours, an additional 2 mL of aDMEM was added to the flasks, followed by incubation at 37° C. with 5% CO2. Cultures were maintained with the replacement of 1 mL of aDMEM every 3 days for up to 10 days' post-inoculation, or until visual observation of ZIKV-induced CPE. Expected ZIKV-induced CPE were perinuclear vacuolation followed by apoptosis. Spent media (2 mL) was collected at initial observation of CPE, cells were refed with 2 mL of aDMEM, and final collections of spent media and lysed cells was taken when CPE were observed in 50% of the monolayer.
- Plaque assays were performed to quantitate PRVABC59 and obtain viral titers, with newly confluent Vero E6 cells in a 6-well plate, to which 250 μL of virus dilutions of 102, 103, 104, 105, and 106 in aDMEM were added to each well. After inoculation, the 6-well plates were rocked every 15 minutes for two hours at 37° C. with 5% CO2. Inocula were then removed, the monolayer washed twice with serum-free Eagle's minimum essential medium (EMEM) and the cells overlaid with 3 mL of 1:1 solution of 1.6% melted agarose with EMEM and 3% low antibody, heat-inactivated, gamma-irradiated FBS with PSN. After the agarose solidified, the plates were incubated upside down for 5 days at 37° C. with 5% CO2, after which an additional 2 mL overlay with 1:1 solution of 1.6% agarose and serum-free EMEM with 0.14 mg/mL neutral red was added. The plaque morphology was then observed, and the number of plaques were counted at 7 days post-infection. A virus stock solution of 1.5×107 plaque-forming unit (PFU)/mL was used for sample spiking and RNA extraction.
- RNA was extracted from 140 μL of Zika virus samples using a QIAamp Viral RNA Mini Kit (QIAGEN, Valencia, Calif., USA) by following the manufacturer's protocol. The collected RNA was eluted with 60 μL of buffer AVE (QIAGEN) and stored at −80° C. before use.
- RNA extracted from Zika virus was used to conduct RT-LAMP. Each of 25 μL RT-LAMP system contains 2.5 μL of 10× isothermal amplification buffer, 2.5 μL of 10× primer mix, 8 U Bst 2.0 WarmStart® DNA Polymerase, 7.5 U WarmStart® RTx Reverse Transcriptase, a final concentration of 1.4 mM dNTPs and 6 mM MgSO4, and 1 μL RNA sample. The 25-4, volume was brought up by molecular-biology-grade water. Except for the dNTPs from ThermoFisher Scientific (MA, USA), other reagents in the RT-LAMP system were obtained from New England Biolabs (Ipswich, Mass., USA). The primer mix contains 1.6 μM F1P/B1P, 0.2 μM F3/B3, and 0.8 μM LF/LB, and the sequences of possible primers are listed below in Table 2. The primers were designed following the literature and obtained from Integrated DNA Technologies (Coralville, Iowa, USA). The inventors used the first set of primers in Table 2 though other sets of primers can be used, as will be understood by those of skill in the art in view of the description provided herein. To perform the amplification, the RT-LAMP system was incubated at 67° C. for 30 minutes in a Bio-Rad Mycycler® (Bio-Raid, CA, USA). The amplicons were confirmed with 2% agarose gel electrophoresis. Gel bands were imaged using a Gel Doc™ EZ system (Bio-Rad).
-
TABLE 2 Possible sequences of Zika RT-LAMP primers Primer Sequence (5′-3′) Ref F3 TTGTCAGGCTCCTGTCAA 7 B3 TTGCTACGAACCTTGTTGAT FIP TGGCACCCTAGTGTCCACTTTTTAGGAATAGCCATGACCGA BIP CAAGAAGGCACTCGTCAGGTTTTGTGTTTGCCTAGCTCTTT LF TGCTGACCATACGGTGTG LB GGTCTCTTCCTGGTTGTGG F3 CAGTTCACACGGCCCTTG 8 B3 TGTACCTCCACTGTGACTGT FIP GGCGACATTTCAAGTGGCCAGAGAGCTCTAGAGGCTGAGA BIP AGGGCGTGTCATACTCCTTGTGAGTGTTTCAGCCGGGATCT LF CCTTCCCTTTGCACCATCCA LB TACCGCAGCGTTCACATTCA F3 TGGAGGGACAGGTACAAGT 9 B3 TGTGGACCTCTCCACATGG FIP CGCAGATACCATCTTCCCAGGCATCCTGACTCCCCCCGTA BIP AAGGGGAGCTCAACGCAATCCGATCCCACAACGACCGTC LF TGCTTGACTGCTGCTGCC F3 TGACATCCCATTGCCTTGG 10 B3 CTTCCCTTTGCACCATCCAT FIP GGCGTGGGCATCCTTGAATTCTGCAGACACCGGAACTCCA BIP GGCAAACCGTCGTCGTTCTGGCTCAGCCTCTAGAGCTCCA LF TGCCTCTTTGTTGTTCCAGTG LB AGCCGTTCACACGGCTC F3 CGGATGGGATAGGCTCAAAC 11 B3 ATGGACCTCCCGTCCTTG FIP CCTGAGGGCATGTGCAAACCTAGAATGGCAGTCAGTGGAG AT BIP ACCCTCAACTGGATGGGACAACTGGAGCTTGTTGAAGTGG TG LF CATCAATTGGCTTCACAACGC LB GGGAAGAAGTTCCGTTTTGCTC F3 GACTTCTGCTGGGTCATG 12 B3 GCCAACAATTCCGACACTA FIP CCCCACTGAACCCCATCTATTGGGTCTTGGCGATTCTAGC BIP GTTCAAGAAAGATCTGGCTGCCCCTCGTCTTCTTCTTCTC CT LF GCTTGATTGCCGTGAATCTC LB GCTGAGAATAATCAATGCCAGG Note: FIP stands for Forward Inner Primer; BIP stands for Backward Inner Primer; LF and LB are the forward and backward loop primers. - For real-time detection of the RT-LAMP assay, 0.5 μL of 1:1000 diluted 10,000× concentrate SYBR green I nucleic acid gel stain in DMSO and 0.5 μL ROX reference dye (ThermoFisher Scientific) were added to the 25 μL RT-LAMP reaction buffer. The fluorescence signal was read through the
QuantStudio 3 real-time PCR system (ThermoFisher Scientific). - Zika samples were made by spiking 1 μL Zika virus at various concentrations to 140 μL of media. Water, human urine, and human saliva (Innovative Research, Novi, Mich.) were used to test the VLEAD's sensitivity. For safety concern, the Zika virus samples were mixed with the AVL lysis buffer (QIAGEN) at the ratio of 1:4 in a biosafety facility before bringing out to perform the test.
-
FIGS. 9A-9F depict the method for using the apparatus shown inFIGS. 7A-7D to perform testing. Two washing buffers (AW1 and AW2 buffer in QIAamp Viral RNA mini Kit) of 200 μL each, a binding buffer (200 proof ethanol) of 560 μL and a lysis buffer of 560 μL (buffer AVL, QIAGEN) were pre-loaded into their designatedreservoirs 21 a-21 d (FIG. 7A ) in theVLEAD buffer unit 21. The Zika virus sample was first loaded into thelysis buffer reservoir 21 d (FIG. 9A ) and discharged into the mixingunit 22 through sliding thebuffer unit 21 to actuate the bearing ball valve (FIG. 9B ), followed by the discharge of bindingbuffer 21 c to mix with the virus lysate in the same manner. Thedetection unit 23 was further placed on a piece of blotting paper to filter the lysate through the laminated paper pad in the detection unit 23 (FIG. 9C ). The paper pad functioned as a SPE material to enrich the Zika virus RNA from the lysate. The time cost by the blotting process depended on the type and volume of Zika sample used. The spiked samples tested by the inventors took no longer than 20 minutes to filter through the paper pad completely. Thebuffer unit 21 was further slid twice to discharge the twowashing buffers FIG. 9D ). - After RNA enrichment, the
buffer unit 21 and mixingunit 22 were separated from thedetection unit 23. To detect the RNA captured, a piece of adhesive tape (Fellows®) was attached to the bottom to prevent amplification buffer leakage. A RT-LAMP amplification buffer of 25 μL was loaded to thedetection unit 23, which was then sealed with another piece of adhesive tape on the top (FIG. 9E ). The sealeddetection unit 23 was incubated either in a travel mug (FIG. 13D ) or in a water bath at 67° C. for 25 minutes in an Isotemp 105 water bath (ThermoFisher Scientific) for DNA amplification. To view the amplification result, 1 μL of 10,000× concentrate SYBR green I nucleic acid gel stain in DMSO (ThermoFisher Scientific) was added to the amplicons after incubation. An ULAKO blue LED flashlight (Amazon, Wash., USA) powered by one AA battery was used to observe the green fluorescence from the positive samples (FIG. 9F ). - To incubate the
detection unit 23 without having to use a standard power supply, the inventors chose to use a commercially available, battery powered coffee mug (FIG. 13D , Ember™ Travel Mug, Ember Technologies, Inc., Westlake Village, Calif.) which can heat water up to 62.5° C. and maintain the temperature for two hours once the rechargeable battery has been fully charged. The Ember™ mug also features adjustable temperature and real-time temperature display, which makes it suitable for incubating isothermal PCR such as the nucleic acid sequence-based amplification (NASBA) and LAMP. To verify the performance of Ember™ mug on RT-LAMP, the inventors purified Zika spiked water samples using theVLEAD apparatus 20, and submerged theVLEAD detection unit 23 directly into the water in the coffee mug after the maximum 62.5° C. had been reached. Thedetection unit 23 was incubated for 25 minutes before being taken out to check the amplification result. -
FIG. 10A is a plot depicting curves 101-103 representing normalized fluorescent signals of 5, 50, and 500 PFU Zika virus genome equivalents amplification by RT-LAMP, respectively, showing that all samples' amplification signals reached the plateau in 15 min.Curve 104 represents NTC.FIG. 10B depicts a standard curve (log PFU per reaction vs. threshold time) generated with three replicates of each of the serial diluted Zika virus RNA samples. The QIAamp Viral RNA Mini Kit (QIAGEN) was used as a bench top standard to purify RNA from Zika virus spiked water. Fluorescence readings were taken from RT-LAMP containing 5, 50 and 500 PFU RNA equivalents using theQuantStudio 3 real-time PCR system (FIG. 10 ). All the positive wells were amplified within 15 minutes, and no non-specific amplification was observed during the 30-minute incubation period. - To evaluate the performance of the VLEAD to detect Zika virus in different kinds of aqueous sample, Zika virus was spiked in molecular-biology-grade water, humane urine, and human saliva. Each sample type with three or six duplicates were processed with the VLEAD apparatus 20 (
FIGS. 7A-7D ) to test its sensitivity. Its qualitative performance was also compared with bench top testing using the QIAamp Viral RNA mini kit (QIAGEN) and Zika virus spiked water (Table 3 below). In the bench top testing, the dilution factor of the elution buffer from the QIAGEN kit was taken into consideration to calculate the number of PFU Zika virus genome equivalents in each test. -
TABLE 3 Zika virus detection using the VLEAD and bench top system. The number of positive results/number of tests. NTC (no-template control) Sample Type 1 PFU 0.5 PFU 0.1 PFU NTC Device Water 3/3 3/3 3/3 0/3 Urine 3/3 3/3 1/3 0/4 Saliva 3/3 3/3 5/6 0/6 Bench Top Water 3/3 3/3 1/3 0/3 -
FIGS. 11A-11C are photographs of thedetection unit 23 corresponding to the results under the ambient light (FIG. 11A ) and blue LED flashlight (FIG. 11B ). The number of Zika virus in PFU spiked per device (1, 0.5, 0.1 PFU and NTC) labeled on the left of each device.FIG. 11C shows a gel electrophoresis image of the amplicons from each device. From left lane to right: 100 bp DNA marker, 1, 0.5, 0.1 PFU and NTC. The results shown inFIGS. 11A-11C indicate that theVLEAD apparatus 20 achieved comparable performance with the commercial QIAGEN kit, with 3/3 detected from 0.1 PFU Zika virus spiked water samples using theVLEAD apparatus 20 and method versus ⅓ detected using the QIAGEN kit. In the case of detecting Zika virus from body fluids such as urine and saliva, the impurities in those samples only affected the sensitivity slightly, with ⅓ 0.1 PFU Zika spiked urine detected and ⅚ 0.1 PFU Zika spiked saliva detected. Compared to bench top testing using the QIAGEN kit, theVLEAD apparatus 20 and method integrate all of the steps required for virus nucleic acid amplification test, from virus lysis, nucleic acid enrichment, purification, to amplification. As a result, there is no need to transfer RNA samples between different tubes, which greatly reduces the chance of sample contamination. - The RNA enrichment process of the
VLEAD apparatus 20 is driven by the capillary forces generated by the laminated paper pad and blotting paper, thus eliminating the need to use lab equipment such as, for example, a centrifuge. Moreover, for an SPE approach using a spin column such as the QIAGEN kit, the RNA purified on the column needs to be eluted before downstream application. The elution step leads to sample dilution and comes with a “dead volume” absorbed on the column. In contrast, with theVLEAD apparatus 20 and method, all of the RNA purified on the paper pad could be used for nucleic acid amplification testing such as reverse transcription polymerase chain reactions (RT-PCR). It should also be noted that isothermal DNA amplification techniques other than LAMP, including strand displacement amplification (SDA) and helicase-dependent amplification (HDA), can also be used, as will be understood by those of skill in the art in view of the description provided herein. - To verify the detection result without lab instruments, the VLEAD method employed SYBR green to visualize the DNA amplicons through the green fluorescence excited by a handheld blue LED flashlight (
FIG. 9F ) from the DNA-dye-complex. Due to the high concentration of SYBR green required by naked-eye observation inhibiting the RT-LAMP enzymes, the dye was not included within the RT-LAMP buffer before the incubation step. Other known colorimetric approaches, such as, for example, those that use hydroxynaphthol blue, leuco crystal violet or phenol red, detect the by-products of RT-LAMP. These approaches often have less differences between the positive and negative results and therefore weren't incorporated into the VLEAD method of the representative embodiment. - Using the
VLEAD apparatus 20, the inventors also tested a de-identified clinical urine sample collected from one Zika patient in Venezuela in 2016. The presence of Zika virus had been confirmed using plaque assay. The sample had been stored in a −80° C. freezer for two years before being tested using theVLEAD apparatus 20 and method. During the testing, the inventors observed slow filtration during the RNA enrichment step. As a result, the inventors reduced the sample volume to 100 μL to keep the blotting time around 20 minutes. A positive control of 10 PFU Zika virus spiked water and a negative control of DI water were made to validate the assay. -
FIGS. 12A-12C are photographs of thedetection unit 23 showing the test results.FIG. 12A is a photograph of thedetection unit 23 under ambient light andFIG. 12B is a photograph of thedetection unit 23 under a blue LED flashlight.FIG. 12C is a gel electrophoresis image of the amplicons from each device; from left lane to right: 100 bp DNA marker, positive control (P), clinical sample (S), and NTC. The presence of Zika virus was detected but the signal was somewhat weak, probably due to RNA degradation during the sample storage. The inventors repeated the experiment using two more aliquots from the same patient and were able to detect ⅔ of all the three aliquots. - The slow filtration observed in this testing could be caused by an increased amount of cell debris in the patient's urine related to disease progression or precipitations formed during the two-year storage. This issue is expected to be significantly less in fresh samples. Further it could potentially be solved by diluting the sample with water or digesting the sample with Proteinase K before sample loading.
- Using the Ember™ travel mug as an incubator for RT-LAMP, the inventors successfully detected the 100, 10, and 1 PFU Zika RNA equivalents purified in the
VLEAD apparatus 20 in 25 minutes (FIGS. 13A-13D ).FIG. 13A is a photograph of thedetection unit 23 under ambient light andFIG. 13B is a photograph of thedetection unit 23 under a blue LED flashlight.FIG. 13C is a gel electrophoresis image of the amplicons from each device; from left lane to right: 100 bp DNA marker, positive control (P), clinical sample (S), and NTC. The cup shown inFIG. 13D has a volume capacity of 12 oz. which is more than enough volume to submerge thedetection unit 23. The cup was filled close to the “MAX” line to reduce the temperature fluctuation upon adding thedetection units 23 during the test. Even though the primer set that was used was optimized at 67° C., which is above the maximum temperature achievable by the Ember™ coffee mug without further customization, the LAMP method is sufficiently robust at a range of temperatures from 57° C. to 67° C. -
FIG. 14 is a plot of atemperature calibration curve 140 for calibrating the Ember™ mug shown inFIG. 13D . Each data point on thecurve 140 was measured three times with 5 min in between. The temperature of the Ember™ mug was first calibrated using a thermocouple which was inserted through a small opening in the lid designed for pressure release. The water temperature inside the mug was set and measured at 52.5° C., 55.0° C., 57.5° C., 60.0° C., and 62.5° C. Three measurements were taken for each temperature, with 1, 6, and 11 minutes after the temperature displayed by the Ember™ mug App had reached the set temperature. - Another advantage of using the
apparatus 20 shown inFIGS. 7A-7D is that the detection limit in terms of the absolute amount of virus is not lowered as a result of increasing the volume of samples.FIGS. 15A and 15B are photographs showing detection results under ambient light and blue LED flashlight, respectively, obtained by theapparatus 20 shown inFIGS. 7C and 9A-9F for detection of 14 μl of ZIKV-spiked urine samples using thedetection unit 23. Devices 1-4 shown inFIGS. 15A and 15B contain 10, 1, 0.5 and 0.1 PFU ZIKV, respectively.Device 5 functions as the negative control. This detection limit in terms of the absolute amount of virus, 0.5 PFU ZIKV per device, is the same as using 140 μl of ZIKV-spiked urine samples with state-of-the-art system discussed above in Table 3. However, the detection limit in terms of the virus concentration or “PFU per volume” is lowered by 10 times when a large volume of samples is used. The results also suggest that essentially all RNA molecules are captured by the paper pad of the detection unit. - Another aspect of the inventive principles and concepts relates to a method for preparing a sample for use in detecting microorganisms.
FIG. 16 is a flow diagram representing the method in accordance with a representative embodiment.Block 161 represents a step of collecting and holding at least a first liquid sample.Block 162 represents a step of allowing the first liquid sample to interact with at least a second liquid to cause nucleic acids to be released from the first liquid sample.Block 163 represents a step of concentrating nucleic acids that have been released from the first liquid sample.Block 164 represents a step of washing the concentrated nucleic acids using at least third and fourth liquids.Block 165 represents a step of amplifying the concentrated nucleic acids at an isothermal temperature to produce amplified products.Block 166 represents a step of detecting the amplified products. - It should be noted that some of the steps shown in
FIG. 16 may be performed almost simultaneously rather than sequentially from one step to the next. It should also be noted that additional steps not explicitly shown inFIG. 16 may be included in the method and that modifications can be made to the steps shown inFIG. 16 . Persons of skill in the art will understand, in view of the description provided herein. - The
VLEAD apparatus 20 and method achieve comparable sensitivity with a commercial SPE RNA extraction kit. Untreated cellulose has been used as a nucleic acid extraction material since the 1960s. However, its use in nucleic acid SPE is far less common nowadays compared to other materials such as silica2 and chitosan. The mechanism of RNA absorption by cellulose fibers is also poorly understood due to lack of study. On the other hand, theVLEAD detection unit 23 made of laminated cellulose paper is uncomplicated, easy-to-use, of low cost and very sensitive in detecting RNA. The above results indicate that cellulose chromatography paper is a good alternative in developing platforms for nucleic acid extraction. - The
VLEAD apparatus 20 was tested with human saliva and urine samples spiked with Zika virus. The disposable, 3D printed components allow the laminated paper pad to process a much larger sample volume (˜100 μL) compared to traditional microfluidic paper-based analytical devices (less than 10 μL) and thus increase the sensitivity of theVLEAD apparatus 20. TheVLEAD apparatus 20 was able to stably detect 0.5 PFU from Zika virus spiked urine and salvia and 0.1 PFU from Zika virus spiked water. - Thus, the
VLEAD apparatus 20 and method can be used to perform an innovative and highly sensitive POC test for Zika virus and other viruses using paper and 3D printed materials. The VLEAD platform can also be used in detecting other microorganisms with different primers for RT-LAMP or other DNA amplification techniques. - Although the
apparatuses apparatuses - The apparatus and method described above with reference to
FIGS. 7A-7C were used to detect SARS-CoV-2. The detection results will now be described. Each 25-4, RT-LAMP mix contains 2.5 μL of 10× isothermal amplification buffer, 8 U Bst 2.0 WarmStart® DNA polymerase, 7.5 U WarmStart® RTx reverse transcriptase, 2.5 μL of 10× concentrated primer mix, and a final concentration of 1.4 mM dNTPs and 6 mM MgSO4. The 25-μL volume was filled up by nuclease-free water (not DEPC treated). Except for the nuclease-free water and dNTPs from ThermoFisher Scientific (MA, USA), the other reagents in the RT-LAMP mix were obtained from New England Biolabs (Ipswich, Mass., USA). The 10× primer mix for SARS-CoV-2 contains 16 μM FIP/BIP, 2 μM F3/B3, and 8 μM LF/LB (Table 4 below). The primers were obtained from Integrated DNA Technologies (Coralville, Iowa, USA), and were chosen by following the literature. - For each 25-4, UDG RT-LAMP reaction mix, 0.5 units of Antarctic Thermolabile uracil-DNA glycosylase (UDG), and 0.7 mM of dUTP solution (New England Biolabs) were added to the RT-LAMP mix previously described, reducing the amount of nuclease-free water needed for the reaction.
-
TABLE 4 Sequences of RT-LAMP primers for SARS-CoV-2 detection targeting the N gene. Primer name Primer sequence (5′-3′) Bases F3 TGGACCCCAAAATCAGCG 18 B3 AGCCAATTTGGTCATCTGGA 20 FIP CGTTGTTTTGATCGCGCCCC 40 (F1c + F2) ATTACGTTTGGTGGACCCTC BIP ATACTGCGTCTTGGTTCACCGC 41 (B1 + B2c) ATTGGAACGCCTTGTCCTC LF TGCGTTCTCCATTCTGGTTACT 22 LB TCTCACTCAACATGGCAAGGAA 22 There are other RT-LAMP primers targeting N gene and other genes including ORF1a and S gene. - To assess the sensitivity of the RT-LAMP assay for detection of SARS-CoV-2, RNA was extracted from an isolate SARS CoV-2/human/USA/UF-1/2020 in VeroE6 cells. The genome copy equivalents per microliter (GCEs/μL) of the extracted RNA was calculated using a standard curve on a rRT-PCR assay, which was determined to be 1×106 GCEs/μL. 10-fold serial dilutions were made using RNA storage solution (Invitrogen), and 1 μL of purified RNA of the different concentrations was added into 25-4, UDG RT-LAMP reactions, along with a non-template control. The RT-LAMP assay for SARS-CoV-2 detection showed high sensitivity with a low limit of detection of less than 10 GCEs.
- The results were confirmed using gel electrophoresis and are shown in
FIGS. 17A-17D .FIGS. 17A-17D are images depicting sensitivity tests for the SARS-CoV-2 RT-LAMP assay, incubating at 62.5° C. for 25 min. The tests demonstrated the ability to detect as low as a 106 dilution of the purified SARS-CoV-2 RNA that was about 106 GCE per microliter. Thus, the method and apparatus were able to detect less than 10 GCEs. From left to right, the units are in the following order: 104 dilution, 105 dilution, 106 dilution, and a no template control. All of the concentrations were amplified after 25 minutes.FIG. 17A is photo taken under room lights;FIG. 17B is a photo taken under room lights and blue LED;FIG. 17C is a photo taken under blue LED with the room lights off;FIG. 17D shows confirmation of results by gel electrophoresis. - Various Aspects of the Above-Described Inventive Principles and Concepts
- In accordance with one aspect, an apparatus for preparing a sample for use in detecting microorganisms is provided. The apparatus comprises a collector unit, a buffer unit, a mechanical coupling mechanism and a valve mechanism. The collector unit has at least a first reservoir for holding at least a first liquid sample. The buffer unit includes at least second, third and fourth reservoirs for holding at least second, third and fourth liquids, respectively. The mechanical coupling mechanism couples the collector unit and the buffer unit together in a manner that allows a user to create relative movement between the collector unit and the buffer unit by exerting a force on at least one of the buffer unit and the collector unit. The valve mechanism causes the second, third and fourth liquids to be released from the second, third and fourth reservoirs, respectively, into the first reservoir, in turn, when the user creates relative movement between the collector unit and the buffer unit to cause the second, third and fourth reservoirs to come into temporary alignment with the first reservoir for respective time periods.
- In accordance with another aspect, the apparatus further comprises a detection unit removably coupled to the collector unit for detecting microorganisms. The detection unit receives liquid from the first reservoir and can be removed from the collector unit and analyzed to determine whether the liquid received by the detection unit contains a particular microorganism.
- In accordance with another aspect, the collector unit is rotatably coupled to the buffer unit by the mechanical coupling mechanism such that the relative movement is created by the user exerting the force on the buffer unit to cause the buffer unit to rotate relative to the collector unit, thereby causing the second, third and fourth reservoirs to come into temporary alignment with the first reservoir for the respective time periods during which the second, third and fourth liquids are released, in turn, into the first reservoir.
- In accordance with another aspect, the valve mechanism comprises a post, a first valve, a first ball, a second valve, a second ball, a third valve and a third ball. The post has a proximal end connected to a surface of the collector unit and a distal end opposite the proximal end. A first valve opening is disposed in a bottom of the second reservoir. The first ball is movably positioned in the first valve opening when the first valve opening is in a closed state. When the second reservoir is in temporary alignment with the first reservoir, the post comes into contact with the first ball to move the first ball away from the first valve opening to thereby place the first valve opening in an opened state. A second valve opening is disposed in a bottom of the third reservoir. The second ball is movably positioned in the second valve opening when the second valve opening is in a closed state. When the third reservoir is in temporary alignment with the first reservoir, the post comes into contact with the second ball to move the second ball away from the second valve opening to thereby place the second valve opening in an opened state. A third valve opening is disposed in a bottom of the fourth reservoir. The third ball is movably positioned in the third valve opening when the third valve opening is in a closed state. When the fourth reservoir is in temporary alignment with the first reservoir, the post comes into contact with the third ball to move the third ball away from the third valve opening to thereby place the third valve opening in an opened state.
- In accordance with another aspect, the detection unit is a paper-based detection unit removably coupled to a bottom side of the collector unit. The first reservoir of the collector unit has an opening therein through which liquid held in the first reservoir passes and is received by the paper-based detection unit.
- In accordance with another aspect, the paper-based detection unit is a laminated paper-based RNA amplification component.
- In accordance with another aspect, the particular microorganism is a virus.
- In accordance with another aspect, the virus is selected from the group comprising influenza virus, Zika virus, Dengue virus, Chikungunya virus, Ebola virus, hepatitis A virus, hepatitis B virus, hepatitis C virus, human immunodeficiency viruses (HIV) and Mayaro virus.
- In accordance with another aspect, the particular microorganism is a bacterium.
- In accordance with another aspect, the bacterium is selected from the group comprising Escherichia coli (E. coli), enterococci, Salmonellae, Streptococcus pneumoniae, Staphylococcus aureus and Pseudomonas aeruginosa.
- In accordance with another aspect, the buffer unit further includes at least fifth reservoir for holding at least a fifth liquid. The valve mechanism causes the second, third, fourth and fifth liquids to be released from the second, third, fourth and fifth reservoirs, respectively, into the first reservoir, in turn, when the user creates relative movement between the collector unit and the buffer unit to cause the second, third, fourth and fifth reservoirs to come into temporary alignment with the first reservoir for respective time periods.
- In accordance with another aspect, the valve mechanism further comprises a fourth valve opening disposed in a bottom of the fifth reservoir and a fourth ball movably positioned in the fourth valve opening when the fourth valve opening is in a closed state. When the fifth reservoir is in temporary alignment with the first reservoir, the post comes into contact with the fourth ball to move the fourth ball away from the fourth valve opening to thereby place the fourth valve opening in an opened state.
- In accordance with another aspect, the collector unit and the buffer unit are slidably coupled to one another by the mechanical coupling mechanism such that when the user exerts the force on at least one of the buffer unit and the collector unit, one of the buffer unit and the collector unit slides relative to the other, thereby causing the second, third, fourth and fifth reservoirs to come into temporary alignment with the first reservoir for the respective time periods during which the second, third, fourth and fifth liquids are released, in turn, into the first reservoir. In accordance with another aspect, the detection unit is a paper-based detection unit removably coupled to a bottom side of the collector unit. The first reservoir of the collector unit has an opening therein through which liquid held in the first reservoir passes and is received by the paper-based detection unit. In accordance with another aspect, the paper-based detection unit is a laminated paper-based RNA amplification component.
- In accordance with another aspect, a method is provided for preparing a sample to be used for detecting microorganisms. The method comprises placing a first liquid sample in at least a first reservoir of a collector unit of a microorganism detecting apparatus, placing at least second, third and fourth liquids in at least second, third and fourth reservoirs, respectively, of a buffer unit of the microorganism detecting apparatus, wherein the collector unit and the buffer unit are coupled together by a mechanical coupling mechanism in a manner that allows a user to create relative movement between the collector unit and the buffer unit by exerting a manual force on at least one of the buffer unit and the collector unit; and exerting the manual force on at least one of the buffer unit and the collector unit to create relative movement between the collector unit and the buffer unit to cause the second, third and fourth reservoirs to come into temporary alignment with the first reservoir for respective time periods, wherein a valve mechanism of the microorganism detecting apparatus causes the second, third and fourth liquids to be released from the second, third and fourth reservoirs, respectively, into the first reservoir, in turn, when the manual force is exerted to cause the second, third and fourth reservoirs to come into temporary alignment with the first reservoir for respective time periods.
- In accordance with another aspect, the method further comprises, with a detection unit removably coupled to the collector unit, receiving liquid from the first reservoir, and removing the detection unit from the collector unit and analyzing the detection unit to determine whether the liquid received by the detection unit contains a particular microorganism.
- In accordance with another aspect, a method is provided for preparing a sample for use in detecting microorganisms comprising, collecting and holding at least a first liquid sample, allowing the first liquid sample to interact with at least a second liquid to cause nucleic acids to be released from the first liquid sample, concentrating nucleic acids that have been released from the first liquid sample, washing the concentrated nucleic acids using at least third and fourth liquids, amplifying the concentrated nucleic acids at an isothermal temperature to produce amplified products, and detecting the amplified products.
- It should be emphasized that the above-described embodiments are merely possible examples of implementations, merely set forth for a clear understanding of the inventive principles and concepts. For example, while the experiment was described with reference to platforms for detecting particular airborne and non-airborne viruses, other types of the apparatuses and methods described herein can be used to detect other types of airborne and non-airborne viruses and microorganisms. Many variations and modifications may be made to the above-described embodiments of the
apparatuses
Claims (20)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/140,696 US20210230533A1 (en) | 2018-07-31 | 2021-01-04 | Apparatus and method for performing microorganism detection |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862712571P | 2018-07-31 | 2018-07-31 | |
PCT/US2019/044490 WO2020028559A1 (en) | 2018-07-31 | 2019-07-31 | Apparatus and method for performing microorganism detection |
US17/140,696 US20210230533A1 (en) | 2018-07-31 | 2021-01-04 | Apparatus and method for performing microorganism detection |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2019/044490 Continuation-In-Part WO2020028559A1 (en) | 2018-07-31 | 2019-07-31 | Apparatus and method for performing microorganism detection |
Publications (1)
Publication Number | Publication Date |
---|---|
US20210230533A1 true US20210230533A1 (en) | 2021-07-29 |
Family
ID=69230552
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/140,696 Pending US20210230533A1 (en) | 2018-07-31 | 2021-01-04 | Apparatus and method for performing microorganism detection |
Country Status (2)
Country | Link |
---|---|
US (1) | US20210230533A1 (en) |
WO (1) | WO2020028559A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11181482B1 (en) * | 2017-10-02 | 2021-11-23 | University Of South Florida | Mobile colorimetric assay device |
WO2023044363A1 (en) * | 2021-09-20 | 2023-03-23 | University Of Florida Research Foundation, Inc. | Multiplex devices and methods for pathogen detection |
WO2023172973A1 (en) * | 2022-03-09 | 2023-09-14 | Yale University | Method of determining personal exposure to a virus |
CN117420305A (en) * | 2021-08-24 | 2024-01-19 | 鲁东大学 | Environment virus prevention detector for poultry containing trapping mechanism |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111856004A (en) * | 2020-03-25 | 2020-10-30 | 潍坊市康华生物技术有限公司 | Reagent for detecting COVID-19 by chemiluminescence immunoassay and detection method thereof |
CN111665356A (en) * | 2020-05-29 | 2020-09-15 | 深圳网联光仪科技有限公司 | SERS-based virus detection method and device |
CN111850172B (en) * | 2020-08-04 | 2023-05-26 | 深圳市梓健生物科技有限公司 | LAMP primer group and kit for detecting SARS-CoV-2 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100159577A1 (en) * | 2008-12-24 | 2010-06-24 | Sanyo Electric Co., Ltd | Automatic culture device, slide valve, and disposable container |
US20150308578A1 (en) * | 2010-10-07 | 2015-10-29 | Vanderbilt University | Normally closed microvalve and applications of the same |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0710957D0 (en) * | 2007-06-07 | 2007-07-18 | Norchip As | A device for carrying out cell lysis and nucleic acid extraction |
CN105378103B (en) * | 2012-12-27 | 2018-01-16 | 成均馆大学校产学协力团 | Using temperature-sensitive polymers compound body nucleic acid amplification disk device and utilize its analysis method |
WO2014152825A1 (en) * | 2013-03-14 | 2014-09-25 | Diagnostics For All, Inc. | Molecular diagnostic devices with magnetic components |
JP2016532075A (en) * | 2013-09-18 | 2016-10-13 | カリフォルニア インスティテュート オブ テクノロジー | System and method for movement and timing control |
-
2019
- 2019-07-31 WO PCT/US2019/044490 patent/WO2020028559A1/en active Application Filing
-
2021
- 2021-01-04 US US17/140,696 patent/US20210230533A1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100159577A1 (en) * | 2008-12-24 | 2010-06-24 | Sanyo Electric Co., Ltd | Automatic culture device, slide valve, and disposable container |
US20150308578A1 (en) * | 2010-10-07 | 2015-10-29 | Vanderbilt University | Normally closed microvalve and applications of the same |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11181482B1 (en) * | 2017-10-02 | 2021-11-23 | University Of South Florida | Mobile colorimetric assay device |
CN117420305A (en) * | 2021-08-24 | 2024-01-19 | 鲁东大学 | Environment virus prevention detector for poultry containing trapping mechanism |
WO2023044363A1 (en) * | 2021-09-20 | 2023-03-23 | University Of Florida Research Foundation, Inc. | Multiplex devices and methods for pathogen detection |
WO2023172973A1 (en) * | 2022-03-09 | 2023-09-14 | Yale University | Method of determining personal exposure to a virus |
Also Published As
Publication number | Publication date |
---|---|
WO2020028559A1 (en) | 2020-02-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210230533A1 (en) | Apparatus and method for performing microorganism detection | |
Song et al. | Point-of-care testing detection methods for COVID-19 | |
Mauk et al. | Miniaturized devices for point of care molecular detection of HIV | |
Liu et al. | A microfluidic-integrated lateral flow recombinase polymerase amplification (MI-IF-RPA) assay for rapid COVID-19 detection | |
Yin et al. | Multiplexed colorimetric detection of SARS-CoV-2 and other pathogens in wastewater on a 3D printed integrated microfluidic chip | |
Zhuang et al. | Advanced “lab-on-a-chip” to detect viruses–Current challenges and future perspectives | |
US11371075B2 (en) | Fully integrated hand-held device to detect specific nucleic acid sequences | |
Jiang et al. | Valve‐enabled sample preparation and RNA amplification in a coffee mug for zika virus detection | |
Zarei | Portable biosensing devices for point-of-care diagnostics: Recent developments and applications | |
Soares et al. | Sample-to-answer COVID-19 nucleic acid testing using a low-cost centrifugal microfluidic platform with bead-based signal enhancement and smartphone read-out | |
Mauk et al. | Microfluidic devices for nucleic acid (NA) isolation, isothermal NA amplification, and real-time detection | |
Verdoy et al. | A novel Real Time micro PCR based Point-of-Care device for Salmonella detection in human clinical samples | |
Jiang et al. | Integration of sample preparation with RNA-Amplification in a hand-held device for airborne virus detection | |
US20180080067A1 (en) | Rapid pertussis diagnosis on a point-of-care hybrid microfluidic biochip | |
Liu et al. | First airborne pathogen direct analysis system | |
US20170022547A1 (en) | Amplification of nanoparticle based assay | |
Howson et al. | Technological advances in veterinary diagnostics: opportunities to deploy rapid decentralised tests to detect pathogens affecting livestock | |
Zhao et al. | Sensitive and rapid detection of Zika virus by loop-mediated isothermal amplification | |
CN105695633B (en) | Hand-foot-and-mouth disease pathogen detection primer sets and kit | |
JP6116540B2 (en) | Luminescence detection method | |
Nascimento Junior et al. | Trends in MERS-CoV, SARS-CoV, and SARS-CoV-2 (COVID-19) diagnosis strategies: A patent review | |
Nyaruaba et al. | SARS-CoV-2/COVID-19 laboratory biosafety practices and current molecular diagnostic tools | |
Seok et al. | Trends of respiratory virus detection in point-of-care testing: A review | |
US20240181444A1 (en) | Multiplex devices and methods for pathogen detection | |
Manzanas et al. | Development of Ball-Enabled Miniaturized Valves for Sample Preparation and Microheaters for Pathogen Detection |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED |
|
AS | Assignment |
Owner name: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED, FLORIDA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FAN, ZHONGHUI HUGH;JIANG, XIAO;TILLY, TREVOR B.;AND OTHERS;REEL/FRAME:056720/0555 Effective date: 20210105 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |